id	sid	tid	token	lemma	pos
cet-1009	1	1	chemical	chemical	NOUN
cet-1009	1	2	engineering	engineering	NOUN
cet-1009	1	3	transactions	transaction	NOUN
cet-1009	1	4	vol	vol	NOUN
cet-1009	1	5	.	.	PROPN
cet-1009	2	1	62	62	NUM
cet-1009	2	2	,	,	PUNCT
cet-1009	2	3	2017	2017	NUM
cet-1009	2	4	a	a	DET
cet-1009	2	5	publication	publication	NOUN
cet-1009	2	6	of	of	ADP
cet-1009	2	7	the	the	DET
cet-1009	2	8	italian	italian	ADJ
cet-1009	2	9	association	association	NOUN
cet-1009	2	10	of	of	ADP
cet-1009	2	11	chemical	chemical	PROPN
cet-1009	2	12	engineering	engineering	NOUN
cet-1009	2	13	online	online	ADV
cet-1009	2	14	at	at	ADP
cet-1009	2	15	www.aidic.it/cet	www.aidic.it/cet	PROPN
cet-1009	2	16	guest	guest	PROPN
cet-1009	2	17	editors	editor	NOUN
cet-1009	2	18	:	:	PUNCT
cet-1009	2	19	fei	fei	PROPN
cet-1009	2	20	song	song	PROPN
cet-1009	2	21	,	,	PUNCT
cet-1009	2	22	haibo	haibo	PROPN
cet-1009	2	23	wang	wang	PROPN
cet-1009	2	24	,	,	PUNCT
cet-1009	2	25	fang	fang	PROPN
cet-1009	2	26	he	he	PRON
cet-1009	2	27	copyright	copyright	NOUN
cet-1009	2	28	©	©	PROPN
cet-1009	2	29	2017	2017	NUM
cet-1009	2	30	,	,	PUNCT
cet-1009	2	31	aidic	aidic	ADJ
cet-1009	2	32	servizi	servizi	PROPN
cet-1009	2	33	s.r.l	s.r.l	PROPN
cet-1009	2	34	.	.	PUNCT
cet-1009	3	1	isbn	isbn	ADJ
cet-1009	3	2	978	978	NUM
cet-1009	3	3	-	-	SYM
cet-1009	3	4	88	88	NUM
cet-1009	3	5	-	-	PUNCT
cet-1009	3	6	9560860	9560860	NUM
cet-1009	3	7	-	-	SYM
cet-1009	3	8	0	0	NUM
cet-1009	3	9	;	;	PUNCT
cet-1009	3	10	issn	issn	PROPN
cet-1009	3	11	2283	2283	NUM
cet-1009	3	12	-	-	SYM
cet-1009	3	13	9216	9216	NUM
cet-1009	3	14	analysis	analysis	NOUN
cet-1009	3	15	on	on	ADP
cet-1009	3	16	chemical	chemical	ADJ
cet-1009	3	17	composition	composition	NOUN
cet-1009	3	18	of	of	ADP
cet-1009	3	19	anti	anti	ADJ
cet-1009	3	20	-	-	ADJ
cet-1009	3	21	rhinitis	rhinitis	ADJ
cet-1009	3	22	drugs	drug	NOUN
cet-1009	3	23	and	and	CCONJ
cet-1009	3	24	study	study	NOUN
cet-1009	3	25	on	on	ADP
cet-1009	3	26	immunopharmacology	immunopharmacology	NOUN
cet-1009	3	27	xiaoyan	xiaoyan	PROPN
cet-1009	3	28	yin	yin	PROPN
cet-1009	3	29	,	,	PUNCT
cet-1009	3	30	hongyong	hongyong	PROPN
cet-1009	3	31	li	li	PROPN
cet-1009	3	32	xingtai	xingtai	PROPN
cet-1009	3	33	medical	medical	PROPN
cet-1009	3	34	college	college	PROPN
cet-1009	3	35	,	,	PUNCT
cet-1009	3	36	xingtai	xingtai	PROPN
cet-1009	3	37	054000	054000	NUM
cet-1009	3	38	,	,	PUNCT
cet-1009	3	39	china	china	PROPN
cet-1009	3	40	yinxiaoyan2000@163.com	yinxiaoyan2000@163.com	X
cet-1009	3	41	based	base	VERB
cet-1009	3	42	on	on	ADP
cet-1009	3	43	the	the	DET
cet-1009	3	44	perspective	perspective	NOUN
cet-1009	3	45	of	of	ADP
cet-1009	3	46	traditional	traditional	ADJ
cet-1009	3	47	chinese	chinese	ADJ
cet-1009	3	48	medicine	medicine	NOUN
cet-1009	3	49	,	,	PUNCT
cet-1009	3	50	this	this	DET
cet-1009	3	51	paper	paper	NOUN
cet-1009	3	52	analyzed	analyze	VERB
cet-1009	3	53	the	the	DET
cet-1009	3	54	pathogenesis	pathogenesis	NOUN
cet-1009	3	55	of	of	ADP
cet-1009	3	56	rhinitis	rhinitis	NOUN
cet-1009	3	57	caused	cause	VERB
cet-1009	3	58	by	by	ADP
cet-1009	3	59	the	the	DET
cet-1009	3	60	deficiency	deficiency	NOUN
cet-1009	3	61	of	of	ADP
cet-1009	3	62	lung	lung	NOUN
cet-1009	3	63	,	,	PUNCT
cet-1009	3	64	spleen	spleen	NOUN
cet-1009	3	65	and	and	CCONJ
cet-1009	3	66	kidney	kidney	NOUN
cet-1009	3	67	,	,	PUNCT
cet-1009	3	68	and	and	CCONJ
cet-1009	3	69	the	the	DET
cet-1009	3	70	invasion	invasion	NOUN
cet-1009	3	71	of	of	ADP
cet-1009	3	72	cold	cold	NOUN
cet-1009	3	73	,	,	PUNCT
cet-1009	3	74	proposed	propose	VERB
cet-1009	3	75	the	the	DET
cet-1009	3	76	combined	combine	VERB
cet-1009	3	77	medicinal	medicinal	ADJ
cet-1009	3	78	components	component	NOUN
cet-1009	3	79	of	of	ADP
cet-1009	3	80	ephedra	ephedra	PROPN
cet-1009	3	81	asarum	asarum	PROPN
cet-1009	3	82	fuzi	fuzi	PROPN
cet-1009	3	83	soup	soup	PROPN
cet-1009	3	84	and	and	CCONJ
cet-1009	3	85	yupingfeng	yupingfeng	PROPN
cet-1009	3	86	san	san	PROPN
cet-1009	3	87	and	and	CCONJ
cet-1009	3	88	conducted	conduct	VERB
cet-1009	3	89	research	research	NOUN
cet-1009	3	90	on	on	ADP
cet-1009	3	91	the	the	DET
cet-1009	3	92	prevention	prevention	NOUN
cet-1009	3	93	and	and	CCONJ
cet-1009	3	94	treatment	treatment	NOUN
cet-1009	3	95	of	of	ADP
cet-1009	3	96	rhinitis	rhinitis	NOUN
cet-1009	3	97	combined	combine	VERB
cet-1009	3	98	with	with	ADP
cet-1009	3	99	the	the	DET
cet-1009	3	100	relevant	relevant	ADJ
cet-1009	3	101	achievements	achievement	NOUN
cet-1009	3	102	in	in	ADP
cet-1009	3	103	immunopharmacology	immunopharmacology	NOUN
cet-1009	3	104	,	,	PUNCT
cet-1009	3	105	providing	provide	VERB
cet-1009	3	106	a	a	DET
cet-1009	3	107	theoretical	theoretical	ADJ
cet-1009	3	108	reference	reference	NOUN
cet-1009	3	109	for	for	ADP
cet-1009	3	110	clinical	clinical	ADJ
cet-1009	3	111	drug	drug	NOUN
cet-1009	3	112	development	development	NOUN
cet-1009	3	113	and	and	CCONJ
cet-1009	3	114	rhinitis	rhinitis	ADJ
cet-1009	3	115	treatment	treatment	NOUN
cet-1009	3	116	.	.	PUNCT
cet-1009	4	1	the	the	DET
cet-1009	4	2	conclusion	conclusion	NOUN
cet-1009	4	3	of	of	ADP
cet-1009	4	4	the	the	DET
cet-1009	4	5	study	study	NOUN
cet-1009	4	6	indicated	indicate	VERB
cet-1009	4	7	that	that	SCONJ
cet-1009	4	8	high	high	ADJ
cet-1009	4	9	dose	dose	NOUN
cet-1009	4	10	of	of	ADP
cet-1009	4	11	biminkang	biminkang	NOUN
cet-1009	4	12	could	could	AUX
cet-1009	4	13	significantly	significantly	ADV
cet-1009	4	14	inhibit	inhibit	VERB
cet-1009	4	15	the	the	DET
cet-1009	4	16	anaphylactic	anaphylactic	ADJ
cet-1009	4	17	contraction	contraction	NOUN
cet-1009	4	18	of	of	ADP
cet-1009	4	19	organism	organism	NOUN
cet-1009	4	20	,	,	PUNCT
cet-1009	4	21	retard	retard	VERB
cet-1009	4	22	the	the	DET
cet-1009	4	23	hemangiectasis	hemangiectasis	NOUN
cet-1009	4	24	caused	cause	VERB
cet-1009	4	25	by	by	ADP
cet-1009	4	26	histamine	histamine	NOUN
cet-1009	4	27	and	and	CCONJ
cet-1009	4	28	reduce	reduce	VERB
cet-1009	4	29	the	the	DET
cet-1009	4	30	value	value	NOUN
cet-1009	4	31	of	of	ADP
cet-1009	4	32	od610	od610	PROPN
cet-1009	4	33	.	.	PUNCT
cet-1009	5	1	the	the	DET
cet-1009	5	2	medicinal	medicinal	ADJ
cet-1009	5	3	mechanism	mechanism	NOUN
cet-1009	5	4	of	of	ADP
cet-1009	5	5	high	high	ADJ
cet-1009	5	6	-	-	PUNCT
cet-1009	5	7	dose	dose	NOUN
cet-1009	5	8	biminkang	biminkang	NOUN
cet-1009	5	9	is	be	AUX
cet-1009	5	10	roughly	roughly	ADV
cet-1009	5	11	the	the	DET
cet-1009	5	12	same	same	ADJ
cet-1009	5	13	as	as	ADP
cet-1009	5	14	loratadine	loratadine	NOUN
cet-1009	5	15	.	.	PUNCT
cet-1009	6	1	biminkang	biminkang	PROPN
cet-1009	6	2	can	can	AUX
cet-1009	6	3	effectively	effectively	ADV
cet-1009	6	4	protect	protect	VERB
cet-1009	6	5	the	the	DET
cet-1009	6	6	nasal	nasal	PROPN
cet-1009	6	7	mucosa	mucosa	NOUN
cet-1009	6	8	,	,	PUNCT
cet-1009	6	9	reduce	reduce	VERB
cet-1009	6	10	harmful	harmful	ADJ
cet-1009	6	11	nasal	nasal	PROPN
cet-1009	6	12	secreta	secreta	PROPN
cet-1009	6	13	,	,	PUNCT
cet-1009	6	14	and	and	CCONJ
cet-1009	6	15	reduce	reduce	VERB
cet-1009	6	16	the	the	DET
cet-1009	6	17	immunopharmacology	immunopharmacology	NOUN
cet-1009	6	18	effect	effect	NOUN
cet-1009	6	19	of	of	ADP
cet-1009	6	20	mc	mc	PROPN
cet-1009	6	21	number	number	PROPN
cet-1009	6	22	,	,	PUNCT
cet-1009	6	23	eos	eos	PROPN
cet-1009	6	24	,	,	PUNCT
cet-1009	6	25	sp	sp	NOUN
cet-1009	6	26	and	and	CCONJ
cet-1009	6	27	ige	ige	PROPN
cet-1009	6	28	.	.	PUNCT
cet-1009	7	1	the	the	DET
cet-1009	7	2	treatment	treatment	NOUN
cet-1009	7	3	effect	effect	NOUN
cet-1009	7	4	of	of	ADP
cet-1009	7	5	biminkang	biminkang	NOUN
cet-1009	7	6	on	on	ADP
cet-1009	7	7	ige	ige	PROPN
cet-1009	7	8	is	be	AUX
cet-1009	7	9	superior	superior	ADJ
cet-1009	7	10	to	to	ADP
cet-1009	7	11	that	that	PRON
cet-1009	7	12	of	of	ADP
cet-1009	7	13	loratadine	loratadine	NOUN
cet-1009	7	14	and	and	CCONJ
cet-1009	7	15	is	be	AUX
cet-1009	7	16	also	also	ADV
cet-1009	7	17	superior	superior	ADJ
cet-1009	7	18	to	to	ADP
cet-1009	7	19	xinqin	xinqin	PROPN
cet-1009	7	20	granule	granule	NOUN
cet-1009	7	21	in	in	ADP
cet-1009	7	22	the	the	DET
cet-1009	7	23	reduction	reduction	NOUN
cet-1009	7	24	of	of	ADP
cet-1009	7	25	eos	eos	PROPN
cet-1009	7	26	and	and	CCONJ
cet-1009	7	27	mc	mc	PROPN
cet-1009	7	28	number	number	NOUN
cet-1009	7	29	.	.	PUNCT
cet-1009	8	1	1	1	X
cet-1009	8	2	.	.	X
cet-1009	8	3	introduction	introduction	NOUN
cet-1009	8	4	rhinitis	rhinitis	NOUN
cet-1009	8	5	refers	refer	VERB
cet-1009	8	6	to	to	ADP
cet-1009	8	7	the	the	DET
cet-1009	8	8	hypersensitivity	hypersensitivity	NOUN
cet-1009	8	9	of	of	ADP
cet-1009	8	10	nasal	nasal	ADJ
cet-1009	8	11	mucosa	mucosa	NOUN
cet-1009	8	12	mainly	mainly	ADV
cet-1009	8	13	caused	cause	VERB
cet-1009	8	14	by	by	ADP
cet-1009	8	15	external	external	ADJ
cet-1009	8	16	environment	environment	NOUN
cet-1009	8	17	and	and	CCONJ
cet-1009	8	18	pathogen	pathogen	VERB
cet-1009	8	19	irritation	irritation	NOUN
cet-1009	8	20	and	and	CCONJ
cet-1009	8	21	almost	almost	ADV
cet-1009	8	22	100	100	NUM
cet-1009	8	23	million	million	NUM
cet-1009	8	24	people	people	NOUN
cet-1009	8	25	worldwide	worldwide	ADV
cet-1009	8	26	have	have	VERB
cet-1009	8	27	allergic	allergic	ADJ
cet-1009	8	28	rhinitis	rhinitis	NOUN
cet-1009	8	29	.	.	PUNCT
cet-1009	9	1	the	the	DET
cet-1009	9	2	main	main	ADJ
cet-1009	9	3	symptoms	symptom	NOUN
cet-1009	9	4	of	of	ADP
cet-1009	9	5	rhinitis	rhinitis	NOUN
cet-1009	9	6	are	be	AUX
cet-1009	9	7	blockage	blockage	NOUN
cet-1009	9	8	of	of	ADP
cet-1009	9	9	the	the	DET
cet-1009	9	10	nose	nose	NOUN
cet-1009	9	11	,	,	PUNCT
cet-1009	9	12	running	run	VERB
cet-1009	9	13	nose	nose	NOUN
cet-1009	9	14	and	and	CCONJ
cet-1009	9	15	sneezing	sneeze	VERB
cet-1009	9	16	,	,	PUNCT
cet-1009	9	17	even	even	ADV
cet-1009	9	18	cause	cause	VERB
cet-1009	9	19	severe	severe	ADJ
cet-1009	9	20	sinusitis	sinusitis	NOUN
cet-1009	9	21	,	,	PUNCT
cet-1009	9	22	asthma	asthma	NOUN
cet-1009	9	23	and	and	CCONJ
cet-1009	9	24	dermatitis	dermatitis	PROPN
cet-1009	9	25	(	(	PUNCT
cet-1009	9	26	ciprandi	ciprandi	NOUN
cet-1009	9	27	,	,	PUNCT
cet-1009	9	28	2008	2008	NUM
cet-1009	9	29	;	;	PUNCT
cet-1009	9	30	aziza	aziza	PROPN
cet-1009	9	31	et	et	PROPN
cet-1009	9	32	al	al	PROPN
cet-1009	9	33	.	.	PROPN
cet-1009	9	34	,	,	PUNCT
cet-1009	9	35	2017	2017	NUM
cet-1009	9	36	;	;	PUNCT
cet-1009	9	37	spector	spector	PROPN
cet-1009	9	38	et	et	PROPN
cet-1009	9	39	al	al	PROPN
cet-1009	9	40	.	.	PROPN
cet-1009	9	41	,	,	PUNCT
cet-1009	9	42	2011	2011	NUM
cet-1009	9	43	;	;	PUNCT
cet-1009	9	44	passalacqua	passalacqua	NOUN
cet-1009	9	45	and	and	CCONJ
cet-1009	9	46	durham	durham	PROPN
cet-1009	9	47	,	,	PUNCT
cet-1009	9	48	2007	2007	NUM
cet-1009	9	49	;	;	PUNCT
cet-1009	9	50	ofworkshops	ofworkshop	NOUN
cet-1009	9	51	,	,	PUNCT
cet-1009	9	52	2004	2004	NUM
cet-1009	9	53	;	;	PUNCT
cet-1009	9	54	hansen	hansen	PROPN
cet-1009	9	55	et	et	PROPN
cet-1009	9	56	al	al	PROPN
cet-1009	9	57	.	.	PROPN
cet-1009	9	58	,	,	PUNCT
cet-1009	9	59	2004	2004	NUM
cet-1009	9	60	)	)	PUNCT
cet-1009	9	61	.	.	PUNCT
cet-1009	10	1	at	at	ADP
cet-1009	10	2	present	present	ADJ
cet-1009	10	3	,	,	PUNCT
cet-1009	10	4	clinical	clinical	ADJ
cet-1009	10	5	treatment	treatment	NOUN
cet-1009	10	6	can	can	AUX
cet-1009	10	7	only	only	ADV
cet-1009	10	8	be	be	AUX
cet-1009	10	9	aimed	aim	VERB
cet-1009	10	10	at	at	ADP
cet-1009	10	11	some	some	DET
cet-1009	10	12	specific	specific	ADJ
cet-1009	10	13	symptoms	symptom	NOUN
cet-1009	10	14	.	.	PUNCT
cet-1009	11	1	however	however	ADV
cet-1009	11	2	,	,	PUNCT
cet-1009	11	3	due	due	ADP
cet-1009	11	4	to	to	ADP
cet-1009	11	5	the	the	DET
cet-1009	11	6	large	large	ADJ
cet-1009	11	7	number	number	NOUN
cet-1009	11	8	of	of	ADP
cet-1009	11	9	pathogens	pathogen	NOUN
cet-1009	11	10	in	in	ADP
cet-1009	11	11	the	the	DET
cet-1009	11	12	external	external	ADJ
cet-1009	11	13	environment	environment	NOUN
cet-1009	11	14	and	and	CCONJ
cet-1009	11	15	cold	cold	ADJ
cet-1009	11	16	air	air	NOUN
cet-1009	11	17	,	,	PUNCT
cet-1009	11	18	bacteria	bacteria	NOUN
cet-1009	11	19	in	in	ADP
cet-1009	11	20	the	the	DET
cet-1009	11	21	air	air	NOUN
cet-1009	11	22	and	and	CCONJ
cet-1009	11	23	chemical	chemical	NOUN
cet-1009	11	24	pollution	pollution	NOUN
cet-1009	11	25	can	can	AUX
cet-1009	11	26	not	not	PART
cet-1009	11	27	be	be	AUX
cet-1009	11	28	avoided	avoid	VERB
cet-1009	11	29	,	,	PUNCT
cet-1009	11	30	which	which	PRON
cet-1009	11	31	leads	lead	VERB
cet-1009	11	32	to	to	ADP
cet-1009	11	33	the	the	DET
cet-1009	11	34	fact	fact	NOUN
cet-1009	11	35	that	that	SCONJ
cet-1009	11	36	current	current	ADJ
cet-1009	11	37	rhinitis	rhinitis	ADJ
cet-1009	11	38	treatment	treatment	NOUN
cet-1009	11	39	of	of	ADP
cet-1009	11	40	traditional	traditional	ADJ
cet-1009	11	41	chinese	chinese	ADJ
cet-1009	11	42	medicine	medicine	NOUN
cet-1009	11	43	and	and	CCONJ
cet-1009	11	44	western	western	ADJ
cet-1009	11	45	medicine	medicine	NOUN
cet-1009	11	46	is	be	AUX
cet-1009	11	47	far	far	ADV
cet-1009	11	48	from	from	ADP
cet-1009	11	49	reaching	reach	VERB
cet-1009	11	50	satisfactory	satisfactory	ADJ
cet-1009	11	51	results	result	NOUN
cet-1009	11	52	.	.	PUNCT
cet-1009	12	1	traditional	traditional	ADJ
cet-1009	12	2	rhinitis	rhinitis	ADJ
cet-1009	12	3	treatment	treatment	NOUN
cet-1009	12	4	methods	method	NOUN
cet-1009	12	5	include	include	VERB
cet-1009	12	6	the	the	DET
cet-1009	12	7	combination	combination	NOUN
cet-1009	12	8	of	of	ADP
cet-1009	12	9	antihistamine	antihistamine	NOUN
cet-1009	12	10	reagents	reagent	NOUN
cet-1009	12	11	,	,	PUNCT
cet-1009	12	12	anticholinergic	anticholinergic	ADJ
cet-1009	12	13	agents	agent	NOUN
cet-1009	12	14	and	and	CCONJ
cet-1009	12	15	stabilizers	stabilizer	NOUN
cet-1009	12	16	,	,	PUNCT
cet-1009	12	17	but	but	CCONJ
cet-1009	12	18	clinical	clinical	ADJ
cet-1009	12	19	treatment	treatment	NOUN
cet-1009	12	20	statistics	statistic	NOUN
cet-1009	12	21	show	show	VERB
cet-1009	12	22	that	that	SCONJ
cet-1009	12	23	the	the	DET
cet-1009	12	24	above	above	ADJ
cet-1009	12	25	drugs	drug	NOUN
cet-1009	12	26	cure	cure	VERB
cet-1009	12	27	only	only	ADV
cet-1009	12	28	the	the	DET
cet-1009	12	29	symptoms	symptom	NOUN
cet-1009	12	30	but	but	CCONJ
cet-1009	12	31	not	not	PART
cet-1009	12	32	the	the	DET
cet-1009	12	33	disease	disease	NOUN
cet-1009	12	34	and	and	CCONJ
cet-1009	12	35	the	the	DET
cet-1009	12	36	symptoms	symptom	NOUN
cet-1009	12	37	may	may	AUX
cet-1009	12	38	repeat	repeat	VERB
cet-1009	12	39	(	(	PUNCT
cet-1009	12	40	marple	marple	NOUN
cet-1009	12	41	,	,	PUNCT
cet-1009	12	42	2008	2008	NUM
cet-1009	12	43	;	;	PUNCT
cet-1009	12	44	gelfand	gelfand	PROPN
cet-1009	12	45	,	,	PUNCT
cet-1009	12	46	2004	2004	NUM
cet-1009	12	47	;	;	PUNCT
cet-1009	12	48	nabe	nabe	PROPN
cet-1009	12	49	et	et	PROPN
cet-1009	12	50	al	al	PROPN
cet-1009	12	51	.	.	PROPN
cet-1009	12	52	,	,	PUNCT
cet-1009	12	53	2014	2014	NUM
cet-1009	12	54	;	;	PUNCT
cet-1009	12	55	brozmanová	brozmanová	PROPN
cet-1009	12	56	et	et	PROPN
cet-1009	12	57	al	al	PROPN
cet-1009	12	58	.	.	PROPN
cet-1009	12	59	,	,	PUNCT
cet-1009	12	60	2006	2006	NUM
cet-1009	12	61	;	;	PUNCT
cet-1009	12	62	scadding	scadding	NOUN
cet-1009	12	63	,	,	PUNCT
cet-1009	12	64	2008	2008	NUM
cet-1009	12	65	;	;	PUNCT
cet-1009	12	66	naclerio	naclerio	PROPN
cet-1009	12	67	,	,	PUNCT
cet-1009	12	68	2010	2010	NUM
cet-1009	12	69	;	;	PUNCT
cet-1009	12	70	liu	liu	PROPN
cet-1009	12	71	et	et	PROPN
cet-1009	12	72	al	al	PROPN
cet-1009	12	73	.	.	PROPN
cet-1009	12	74	,	,	PUNCT
cet-1009	12	75	2014	2014	NUM
cet-1009	12	76	;	;	PUNCT
cet-1009	12	77	miyahara	miyahara	PROPN
cet-1009	12	78	et	et	PROPN
cet-1009	12	79	al	al	PROPN
cet-1009	12	80	.	.	PROPN
cet-1009	12	81	,	,	PUNCT
cet-1009	12	82	2006	2006	NUM
cet-1009	12	83	)	)	PUNCT
cet-1009	12	84	.	.	PUNCT
cet-1009	13	1	based	base	VERB
cet-1009	13	2	on	on	ADP
cet-1009	13	3	the	the	DET
cet-1009	13	4	perspective	perspective	NOUN
cet-1009	13	5	of	of	ADP
cet-1009	13	6	traditional	traditional	ADJ
cet-1009	13	7	chinese	chinese	ADJ
cet-1009	13	8	medicine	medicine	NOUN
cet-1009	13	9	,	,	PUNCT
cet-1009	13	10	this	this	DET
cet-1009	13	11	paper	paper	NOUN
cet-1009	13	12	analyzed	analyze	VERB
cet-1009	13	13	the	the	DET
cet-1009	13	14	pathogenesis	pathogenesis	NOUN
cet-1009	13	15	of	of	ADP
cet-1009	13	16	rhinitis	rhinitis	NOUN
cet-1009	13	17	caused	cause	VERB
cet-1009	13	18	by	by	ADP
cet-1009	13	19	the	the	DET
cet-1009	13	20	deficiency	deficiency	NOUN
cet-1009	13	21	of	of	ADP
cet-1009	13	22	lung	lung	NOUN
cet-1009	13	23	,	,	PUNCT
cet-1009	13	24	spleen	spleen	NOUN
cet-1009	13	25	and	and	CCONJ
cet-1009	13	26	kidney	kidney	NOUN
cet-1009	13	27	,	,	PUNCT
cet-1009	13	28	and	and	CCONJ
cet-1009	13	29	the	the	DET
cet-1009	13	30	invasion	invasion	NOUN
cet-1009	13	31	of	of	ADP
cet-1009	13	32	cold	cold	NOUN
cet-1009	13	33	,	,	PUNCT
cet-1009	13	34	proposed	propose	VERB
cet-1009	13	35	the	the	DET
cet-1009	13	36	combined	combine	VERB
cet-1009	13	37	medicinal	medicinal	ADJ
cet-1009	13	38	components	component	NOUN
cet-1009	13	39	of	of	ADP
cet-1009	13	40	ephedra	ephedra	PROPN
cet-1009	13	41	asarum	asarum	PROPN
cet-1009	13	42	fuzi	fuzi	PROPN
cet-1009	13	43	soup	soup	PROPN
cet-1009	13	44	and	and	CCONJ
cet-1009	13	45	yupingfeng	yupingfeng	PROPN
cet-1009	13	46	san	san	PROPN
cet-1009	13	47	and	and	CCONJ
cet-1009	13	48	conducted	conduct	VERB
cet-1009	13	49	research	research	NOUN
cet-1009	13	50	on	on	ADP
cet-1009	13	51	the	the	DET
cet-1009	13	52	prevention	prevention	NOUN
cet-1009	13	53	and	and	CCONJ
cet-1009	13	54	treatment	treatment	NOUN
cet-1009	13	55	of	of	ADP
cet-1009	13	56	rhinitis	rhinitis	NOUN
cet-1009	13	57	combined	combine	VERB
cet-1009	13	58	with	with	ADP
cet-1009	13	59	the	the	DET
cet-1009	13	60	relevant	relevant	ADJ
cet-1009	13	61	achievements	achievement	NOUN
cet-1009	13	62	in	in	ADP
cet-1009	13	63	immunopharmacology	immunopharmacology	NOUN
cet-1009	13	64	,	,	PUNCT
cet-1009	13	65	providing	provide	VERB
cet-1009	13	66	a	a	DET
cet-1009	13	67	theoretical	theoretical	ADJ
cet-1009	13	68	reference	reference	NOUN
cet-1009	13	69	for	for	ADP
cet-1009	13	70	clinical	clinical	ADJ
cet-1009	13	71	drug	drug	NOUN
cet-1009	13	72	development	development	NOUN
cet-1009	13	73	and	and	CCONJ
cet-1009	13	74	rhinitis	rhinitis	NOUN
cet-1009	13	75	treatment	treatment	NOUN
cet-1009	13	76	(	(	PUNCT
cet-1009	13	77	canonica	canonica	NOUN
cet-1009	13	78	et	et	PROPN
cet-1009	13	79	al	al	PROPN
cet-1009	13	80	.	.	PROPN
cet-1009	13	81	,	,	PUNCT
cet-1009	13	82	2010	2010	NUM
cet-1009	13	83	;	;	PUNCT
cet-1009	13	84	mandhane	mandhane	PROPN
cet-1009	13	85	et	et	PROPN
cet-1009	13	86	al	al	PROPN
cet-1009	13	87	.	.	PROPN
cet-1009	13	88	,	,	PUNCT
cet-1009	13	89	2011	2011	NUM
cet-1009	13	90	)	)	PUNCT
cet-1009	13	91	.	.	PUNCT
cet-1009	14	1	2	2	X
cet-1009	14	2	.	.	X
cet-1009	14	3	pharmacological	pharmacological	ADJ
cet-1009	14	4	effect	effect	NOUN
cet-1009	14	5	of	of	ADP
cet-1009	14	6	anti	anti	ADJ
cet-1009	14	7	-	-	ADJ
cet-1009	14	8	rhinitis	rhinitis	ADJ
cet-1009	14	9	medicine	medicine	NOUN
cet-1009	14	10	on	on	ADP
cet-1009	14	11	the	the	DET
cet-1009	14	12	contraction	contraction	NOUN
cet-1009	14	13	and	and	CCONJ
cet-1009	14	14	inhibition	inhibition	NOUN
cet-1009	14	15	of	of	ADP
cet-1009	14	16	individual	individual	ADJ
cet-1009	14	17	allergy	allergy	NOUN
cet-1009	14	18	2.1	2.1	NUM
cet-1009	14	19	test	test	NOUN
cet-1009	14	20	materials	material	NOUN
cet-1009	14	21	and	and	CCONJ
cet-1009	14	22	methods	method	NOUN
cet-1009	14	23	allergic	allergic	ADJ
cet-1009	14	24	contraction	contraction	NOUN
cet-1009	14	25	test	test	NOUN
cet-1009	14	26	on	on	ADP
cet-1009	14	27	rats	rat	NOUN
cet-1009	14	28	:	:	PUNCT
cet-1009	14	29	adult	adult	NOUN
cet-1009	14	30	male	male	NOUN
cet-1009	14	31	rats	rat	NOUN
cet-1009	14	32	fed	feed	VERB
cet-1009	14	33	a	a	DET
cet-1009	14	34	laboratory	laboratory	NOUN
cet-1009	14	35	diet	diet	NOUN
cet-1009	14	36	are	be	AUX
cet-1009	14	37	selected	select	VERB
cet-1009	14	38	,	,	PUNCT
cet-1009	14	39	weighing	weigh	VERB
cet-1009	14	40	140	140	NUM
cet-1009	14	41	-	-	SYM
cet-1009	14	42	180	180	NUM
cet-1009	14	43	g	g	NOUN
cet-1009	14	44	;	;	PUNCT
cet-1009	14	45	vascular	vascular	ADJ
cet-1009	14	46	permeability	permeability	NOUN
cet-1009	14	47	test	test	NOUN
cet-1009	14	48	on	on	ADP
cet-1009	14	49	rats	rat	NOUN
cet-1009	14	50	:	:	PUNCT
cet-1009	14	51	adult	adult	NOUN
cet-1009	14	52	male	male	NOUN
cet-1009	14	53	rats	rat	NOUN
cet-1009	14	54	fed	feed	VERB
cet-1009	14	55	a	a	DET
cet-1009	14	56	laboratory	laboratory	NOUN
cet-1009	14	57	diet	diet	NOUN
cet-1009	14	58	are	be	AUX
cet-1009	14	59	selected	select	VERB
cet-1009	14	60	,	,	PUNCT
cet-1009	14	61	weighing	weigh	VERB
cet-1009	14	62	140	140	NUM
cet-1009	14	63	-	-	SYM
cet-1009	14	64	180	180	NUM
cet-1009	14	65	g.	g.	NOUN
cet-1009	14	66	the	the	DET
cet-1009	14	67	test	test	NOUN
cet-1009	14	68	temperature	temperature	NOUN
cet-1009	14	69	is	be	AUX
cet-1009	14	70	25	25	NUM
cet-1009	14	71	°	°	NOUN
cet-1009	14	72	c	c	NOUN
cet-1009	14	73	;	;	PUNCT
cet-1009	14	74	the	the	DET
cet-1009	14	75	relative	relative	ADJ
cet-1009	14	76	humidity	humidity	NOUN
cet-1009	14	77	is	be	AUX
cet-1009	14	78	60	60	NUM
cet-1009	14	79	%	%	NOUN
cet-1009	14	80	,	,	PUNCT
cet-1009	14	81	two	two	NUM
cet-1009	14	82	types	type	NOUN
cet-1009	14	83	of	of	ADP
cet-1009	14	84	rats	rat	NOUN
cet-1009	14	85	were	be	AUX
cet-1009	14	86	fed	feed	VERB
cet-1009	14	87	10d	10d	NOUN
cet-1009	14	88	before	before	ADP
cet-1009	14	89	the	the	DET
cet-1009	14	90	relevant	relevant	ADJ
cet-1009	14	91	tests	test	NOUN
cet-1009	14	92	.	.	PUNCT
cet-1009	15	1	doi	doi	NOUN
cet-1009	15	2	:	:	PUNCT
cet-1009	15	3	10.3303	10.3303	NUM
cet-1009	15	4	/	/	SYM
cet-1009	15	5	cet1762211	cet1762211	NOUN
cet-1009	15	6	please	please	INTJ
cet-1009	15	7	cite	cite	VERB
cet-1009	15	8	this	this	DET
cet-1009	15	9	article	article	NOUN
cet-1009	15	10	as	as	ADP
cet-1009	15	11	:	:	PUNCT
cet-1009	15	12	xiaoyan	xiaoyan	PROPN
cet-1009	15	13	yin	yin	PROPN
cet-1009	15	14	,	,	PUNCT
cet-1009	15	15	hongyong	hongyong	PROPN
cet-1009	15	16	li	li	PROPN
cet-1009	15	17	,	,	PUNCT
cet-1009	15	18	2017	2017	NUM
cet-1009	15	19	,	,	PUNCT
cet-1009	15	20	analysis	analysis	NOUN
cet-1009	15	21	on	on	ADP
cet-1009	15	22	chemical	chemical	ADJ
cet-1009	15	23	composition	composition	NOUN
cet-1009	15	24	of	of	ADP
cet-1009	15	25	anti	anti	ADJ
cet-1009	15	26	-	-	ADJ
cet-1009	15	27	rhinitis	rhinitis	ADJ
cet-1009	15	28	drugs	drug	NOUN
cet-1009	15	29	and	and	CCONJ
cet-1009	15	30	study	study	NOUN
cet-1009	15	31	on	on	ADP
cet-1009	15	32	immunopharmacology	immunopharmacology	NOUN
cet-1009	15	33	,	,	PUNCT
cet-1009	15	34	chemical	chemical	ADJ
cet-1009	15	35	engineering	engineering	NOUN
cet-1009	15	36	transactions	transaction	NOUN
cet-1009	15	37	,	,	PUNCT
cet-1009	15	38	62	62	NUM
cet-1009	15	39	,	,	PUNCT
cet-1009	15	40	1261	1261	NUM
cet-1009	15	41	-	-	SYM
cet-1009	15	42	1266	1266	NUM
cet-1009	15	43	doi:10.3303	doi:10.3303	NOUN
cet-1009	15	44	/	/	SYM
cet-1009	15	45	cet1762211	cet1762211	ADJ
cet-1009	15	46	1261	1261	NUM
cet-1009	15	47	test	test	NOUN
cet-1009	15	48	drugs	drug	NOUN
cet-1009	15	49	:	:	PUNCT
cet-1009	15	50	biminkang	biminkang	PROPN
cet-1009	15	51	,	,	PUNCT
cet-1009	15	52	loratadine	loratadine	NOUN
cet-1009	15	53	,	,	PUNCT
cet-1009	15	54	histamine	histamine	NOUN
cet-1009	15	55	phosphate	phosphate	NOUN
cet-1009	15	56	,	,	PUNCT
cet-1009	15	57	qulibenlan	qulibenlan	NOUN
cet-1009	15	58	;	;	PUNCT
cet-1009	15	59	experimental	experimental	ADJ
cet-1009	15	60	equipment	equipment	NOUN
cet-1009	15	61	:	:	PUNCT
cet-1009	15	62	constant	constant	ADJ
cet-1009	15	63	temperature	temperature	NOUN
cet-1009	15	64	water	water	NOUN
cet-1009	15	65	bath	bath	NOUN
cet-1009	15	66	,	,	PUNCT
cet-1009	15	67	photometer	photometer	NOUN
cet-1009	15	68	,	,	PUNCT
cet-1009	15	69	biological	biological	ADJ
cet-1009	15	70	machine	machine	NOUN
cet-1009	15	71	test	test	NOUN
cet-1009	15	72	system	system	NOUN
cet-1009	15	73	.	.	PUNCT
cet-1009	16	1	the	the	DET
cet-1009	16	2	spss	spss	PROPN
cet-1009	16	3	is	be	AUX
cet-1009	16	4	used	use	VERB
cet-1009	16	5	to	to	PART
cet-1009	16	6	carry	carry	VERB
cet-1009	16	7	out	out	ADP
cet-1009	16	8	the	the	DET
cet-1009	16	9	post	post	NOUN
cet-1009	16	10	data	datum	NOUN
cet-1009	16	11	processing	processing	NOUN
cet-1009	16	12	.	.	PUNCT
cet-1009	17	1	test	test	NOUN
cet-1009	17	2	procedure	procedure	NOUN
cet-1009	17	3	:	:	PUNCT
cet-1009	17	4	the	the	DET
cet-1009	17	5	rats	rat	NOUN
cet-1009	17	6	for	for	ADP
cet-1009	17	7	allergic	allergic	ADJ
cet-1009	17	8	contraction	contraction	NOUN
cet-1009	17	9	and	and	CCONJ
cet-1009	17	10	vascular	vascular	ADJ
cet-1009	17	11	permeability	permeability	NOUN
cet-1009	17	12	test	test	NOUN
cet-1009	17	13	are	be	AUX
cet-1009	17	14	divided	divide	VERB
cet-1009	17	15	into	into	ADP
cet-1009	17	16	low	low	ADJ
cet-1009	17	17	dose	dose	NOUN
cet-1009	17	18	(	(	PUNCT
cet-1009	17	19	2.5	2.5	NUM
cet-1009	17	20	mg	mg	PROPN
cet-1009	17	21	/	/	SYM
cet-1009	17	22	ml	ml	NOUN
cet-1009	17	23	)	)	PUNCT
cet-1009	17	24	,	,	PUNCT
cet-1009	17	25	middle	middle	PROPN
cet-1009	17	26	dose	dose	PROPN
cet-1009	17	27	(	(	PUNCT
cet-1009	17	28	5.0	5.0	NUM
cet-1009	17	29	mg	mg	NOUN
cet-1009	17	30	/	/	SYM
cet-1009	17	31	ml	ml	NOUN
cet-1009	17	32	)	)	PUNCT
cet-1009	17	33	and	and	CCONJ
cet-1009	17	34	high	high	ADJ
cet-1009	17	35	dose	dose	NOUN
cet-1009	17	36	group	group	NOUN
cet-1009	17	37	(	(	PUNCT
cet-1009	17	38	10.0	10.0	NUM
cet-1009	17	39	mg	mg	PROPN
cet-1009	17	40	/	/	SYM
cet-1009	17	41	ml	ml	NOUN
cet-1009	17	42	)	)	PUNCT
cet-1009	17	43	and	and	CCONJ
cet-1009	17	44	no	no	ADV
cet-1009	17	45	-	-	PUNCT
cet-1009	17	46	dose	dose	NOUN
cet-1009	17	47	control	control	NOUN
cet-1009	17	48	group	group	NOUN
cet-1009	17	49	.	.	PUNCT
cet-1009	18	1	before	before	ADP
cet-1009	18	2	the	the	DET
cet-1009	18	3	experiment	experiment	NOUN
cet-1009	18	4	,	,	PUNCT
cet-1009	18	5	rats	rat	NOUN
cet-1009	18	6	are	be	AUX
cet-1009	18	7	injected	inject	VERB
cet-1009	18	8	with	with	ADP
cet-1009	18	9	normal	normal	ADJ
cet-1009	18	10	saline	saline	NOUN
cet-1009	18	11	into	into	ADP
cet-1009	18	12	the	the	DET
cet-1009	18	13	hind	hind	NOUN
cet-1009	18	14	leg	leg	NOUN
cet-1009	18	15	and	and	CCONJ
cet-1009	18	16	abdominal	abdominal	ADJ
cet-1009	18	17	cavity	cavity	NOUN
cet-1009	18	18	.	.	PUNCT
cet-1009	19	1	rats	rat	NOUN
cet-1009	19	2	are	be	AUX
cet-1009	19	3	sacrificed	sacrifice	VERB
cet-1009	19	4	after	after	ADP
cet-1009	19	5	5	5	NUM
cet-1009	19	6	weeks	week	NOUN
cet-1009	19	7	of	of	ADP
cet-1009	19	8	feeding	feeding	NOUN
cet-1009	19	9	and	and	CCONJ
cet-1009	19	10	the	the	DET
cet-1009	19	11	ileum	ileum	NOUN
cet-1009	19	12	is	be	AUX
cet-1009	19	13	quickly	quickly	ADV
cet-1009	19	14	taken	take	VERB
cet-1009	19	15	and	and	CCONJ
cet-1009	19	16	placed	place	VERB
cet-1009	19	17	in	in	ADP
cet-1009	19	18	the	the	DET
cet-1009	19	19	nutrient	nutrient	NOUN
cet-1009	19	20	solution	solution	NOUN
cet-1009	19	21	.	.	PUNCT
cet-1009	20	1	the	the	DET
cet-1009	20	2	antigen	antigen	NOUN
cet-1009	20	3	,	,	PUNCT
cet-1009	20	4	as	as	ADV
cet-1009	20	5	well	well	ADV
cet-1009	20	6	as	as	ADP
cet-1009	20	7	the	the	DET
cet-1009	20	8	medicine	medicine	NOUN
cet-1009	20	9	,	,	PUNCT
cet-1009	20	10	is	be	AUX
cet-1009	20	11	injected	inject	VERB
cet-1009	20	12	into	into	ADP
cet-1009	20	13	the	the	DET
cet-1009	20	14	nutrient	nutrient	NOUN
cet-1009	20	15	solution	solution	NOUN
cet-1009	20	16	every	every	DET
cet-1009	20	17	2	2	NUM
cet-1009	20	18	hours	hour	NOUN
cet-1009	20	19	,	,	PUNCT
cet-1009	20	20	the	the	DET
cet-1009	20	21	contraction	contraction	NOUN
cet-1009	20	22	inhibition	inhibition	NOUN
cet-1009	20	23	rate	rate	NOUN
cet-1009	20	24	of	of	ADP
cet-1009	20	25	the	the	DET
cet-1009	20	26	ileum	ileum	NOUN
cet-1009	20	27	is	be	AUX
cet-1009	20	28	recorded	record	VERB
cet-1009	20	29	.	.	PUNCT
cet-1009	21	1	the	the	DET
cet-1009	21	2	vascular	vascular	ADJ
cet-1009	21	3	permeability	permeability	NOUN
cet-1009	21	4	test	test	NOUN
cet-1009	21	5	is	be	AUX
cet-1009	21	6	as	as	ADP
cet-1009	21	7	the	the	DET
cet-1009	21	8	above	above	ADJ
cet-1009	21	9	.	.	PUNCT
cet-1009	22	1	2.2	2.2	NUM
cet-1009	22	2	test	test	NOUN
cet-1009	22	3	results	result	NOUN
cet-1009	22	4	and	and	CCONJ
cet-1009	22	5	analysis	analysis	NOUN
cet-1009	22	6	figure	figure	NOUN
cet-1009	22	7	1	1	NUM
cet-1009	22	8	shows	show	VERB
cet-1009	22	9	the	the	DET
cet-1009	22	10	treatment	treatment	NOUN
cet-1009	22	11	inhibition	inhibition	NOUN
cet-1009	22	12	effect	effect	NOUN
cet-1009	22	13	of	of	ADP
cet-1009	22	14	different	different	ADJ
cet-1009	22	15	doses	dose	NOUN
cet-1009	22	16	of	of	ADP
cet-1009	22	17	biminkang	biminkang	NOUN
cet-1009	22	18	on	on	ADP
cet-1009	22	19	the	the	DET
cet-1009	22	20	allergic	allergic	ADJ
cet-1009	22	21	contraction	contraction	NOUN
cet-1009	22	22	of	of	ADP
cet-1009	22	23	rats	rat	NOUN
cet-1009	22	24	.	.	PUNCT
cet-1009	23	1	as	as	SCONJ
cet-1009	23	2	can	can	AUX
cet-1009	23	3	be	be	AUX
cet-1009	23	4	seen	see	VERB
cet-1009	23	5	from	from	ADP
cet-1009	23	6	the	the	DET
cet-1009	23	7	figure	figure	NOUN
cet-1009	23	8	,	,	PUNCT
cet-1009	23	9	the	the	DET
cet-1009	23	10	effects	effect	NOUN
cet-1009	23	11	of	of	ADP
cet-1009	23	12	biminkang	biminkang	NOUN
cet-1009	23	13	in	in	ADP
cet-1009	23	14	low	low	ADJ
cet-1009	23	15	-	-	PUNCT
cet-1009	23	16	dose	dose	NOUN
cet-1009	23	17	group	group	NOUN
cet-1009	23	18	,	,	PUNCT
cet-1009	23	19	medium	medium	ADJ
cet-1009	23	20	-	-	PUNCT
cet-1009	23	21	dose	dose	NOUN
cet-1009	23	22	group	group	NOUN
cet-1009	23	23	and	and	CCONJ
cet-1009	23	24	high	high	ADJ
cet-1009	23	25	-	-	PUNCT
cet-1009	23	26	dose	dose	NOUN
cet-1009	23	27	group	group	NOUN
cet-1009	23	28	are	be	AUX
cet-1009	23	29	significantly	significantly	ADV
cet-1009	23	30	higher	high	ADJ
cet-1009	23	31	than	than	ADP
cet-1009	23	32	those	those	PRON
cet-1009	23	33	in	in	ADP
cet-1009	23	34	blank	blank	ADJ
cet-1009	23	35	control	control	NOUN
cet-1009	23	36	group	group	NOUN
cet-1009	23	37	,	,	PUNCT
cet-1009	23	38	and	and	CCONJ
cet-1009	23	39	the	the	PRON
cet-1009	23	40	higher	high	ADJ
cet-1009	23	41	the	the	DET
cet-1009	23	42	dose	dose	NOUN
cet-1009	23	43	of	of	ADP
cet-1009	23	44	biminkang	biminkang	NOUN
cet-1009	23	45	,	,	PUNCT
cet-1009	23	46	the	the	DET
cet-1009	23	47	more	more	ADV
cet-1009	23	48	obvious	obvious	ADJ
cet-1009	23	49	the	the	DET
cet-1009	23	50	inhibitory	inhibitory	ADJ
cet-1009	23	51	effect	effect	NOUN
cet-1009	23	52	.	.	PUNCT
cet-1009	24	1	the	the	DET
cet-1009	24	2	pharmacological	pharmacological	ADJ
cet-1009	24	3	effect	effect	NOUN
cet-1009	24	4	of	of	ADP
cet-1009	24	5	10.0mg	10.0mg	NUM
cet-1009	24	6	/	/	SYM
cet-1009	24	7	ml	ml	X
cet-1009	24	8	of	of	ADP
cet-1009	24	9	high	high	ADJ
cet-1009	24	10	-	-	PUNCT
cet-1009	24	11	dose	dose	NOUN
cet-1009	24	12	group	group	NOUN
cet-1009	24	13	is	be	AUX
cet-1009	24	14	basically	basically	ADV
cet-1009	24	15	the	the	DET
cet-1009	24	16	same	same	ADJ
cet-1009	24	17	as	as	ADP
cet-1009	24	18	the	the	DET
cet-1009	24	19	inhibition	inhibition	NOUN
cet-1009	24	20	effect	effect	NOUN
cet-1009	24	21	of	of	ADP
cet-1009	24	22	loratadine	loratadine	NOUN
cet-1009	24	23	.	.	PUNCT
cet-1009	25	1	0	0	NUM
cet-1009	25	2	10	10	NUM
cet-1009	25	3	20	20	NUM
cet-1009	25	4	30	30	NUM
cet-1009	25	5	40	40	NUM
cet-1009	25	6	50	50	NUM
cet-1009	25	7	60	60	NUM
cet-1009	25	8	70	70	NUM
cet-1009	25	9	80	80	NUM
cet-1009	25	10	90	90	NUM
cet-1009	25	11	100	100	NUM
cet-1009	25	12	blank	blank	ADJ
cet-1009	25	13	control	control	PROPN
cet-1009	25	14	biminkang	biminkang	PROPN
cet-1009	25	15	low	low	PROPN
cet-1009	25	16	biminkang	biminkang	PROPN
cet-1009	25	17	middle	middle	PROPN
cet-1009	25	18	biminkang	biminkang	PROPN
cet-1009	25	19	high	high	ADJ
cet-1009	25	20	loratadine	loratadine	NOUN
cet-1009	25	21	in	in	ADP
cet-1009	25	22	hi	hi	INTJ
cet-1009	25	23	bi	bi	NOUN
cet-1009	25	24	tio	tio	PROPN
cet-1009	25	25	n	n	ADV
cet-1009	25	26	ra	ra	PROPN
cet-1009	25	27	te	te	INTJ
cet-1009	25	28	/%	/%	X
cet-1009	25	29	figure	figure	NOUN
cet-1009	25	30	1	1	NUM
cet-1009	25	31	:	:	PUNCT
cet-1009	25	32	treatment	treatment	NOUN
cet-1009	25	33	inhibition	inhibition	NOUN
cet-1009	25	34	effect	effect	NOUN
cet-1009	25	35	comparison	comparison	NOUN
cet-1009	25	36	of	of	ADP
cet-1009	25	37	different	different	ADJ
cet-1009	25	38	doses	dose	NOUN
cet-1009	25	39	of	of	ADP
cet-1009	25	40	biminkang	biminkang	NOUN
cet-1009	25	41	on	on	ADP
cet-1009	25	42	the	the	DET
cet-1009	25	43	allergic	allergic	ADJ
cet-1009	25	44	contraction	contraction	NOUN
cet-1009	25	45	of	of	ADP
cet-1009	25	46	rats	rat	NOUN
cet-1009	25	47	0	0	NUM
cet-1009	25	48	model	model	PROPN
cet-1009	25	49	control	control	PROPN
cet-1009	25	50	biminkang	biminkang	PROPN
cet-1009	25	51	low	low	PROPN
cet-1009	25	52	biminkang	biminkang	PROPN
cet-1009	25	53	middle	middle	PROPN
cet-1009	25	54	biminkang	biminkang	PROPN
cet-1009	25	55	high	high	PROPN
cet-1009	25	56	loratadine	loratadine	PROPN
cet-1009	25	57	lo	lo	PROPN
cet-1009	25	58	cu	cu	PROPN
cet-1009	25	59	s	s	PROPN
cet-1009	26	1	c	c	PROPN
cet-1009	26	2	oe	oe	PROPN
cet-1009	26	3	ru	ru	PROPN
cet-1009	26	4	le	le	PROPN
cet-1009	26	5	us	us	PROPN
cet-1009	26	6	d	d	PROPN
cet-1009	26	7	ia	ia	PROPN
cet-1009	26	8	m	m	VERB
cet-1009	26	9	et	et	NOUN
cet-1009	26	10	er	er	INTJ
cet-1009	26	11	/c	/c	NOUN
cet-1009	26	12	m	m	VERB
cet-1009	26	13	3	3	NUM
cet-1009	26	14	2.5	2.5	NUM
cet-1009	26	15	2	2	NUM
cet-1009	26	16	1.5	1.5	NUM
cet-1009	26	17	1	1	NUM
cet-1009	26	18	0.5	0.5	NUM
cet-1009	26	19	figure	figure	NOUN
cet-1009	26	20	2	2	NUM
cet-1009	26	21	:	:	PUNCT
cet-1009	26	22	comparison	comparison	NOUN
cet-1009	26	23	of	of	ADP
cet-1009	26	24	different	different	ADJ
cet-1009	26	25	doses	dose	NOUN
cet-1009	26	26	of	of	ADP
cet-1009	26	27	biminkang	biminkang	NOUN
cet-1009	26	28	on	on	ADP
cet-1009	26	29	the	the	DET
cet-1009	26	30	skin	skin	NOUN
cet-1009	26	31	locus	locus	NOUN
cet-1009	26	32	coeruleus	coeruleus	NOUN
cet-1009	26	33	diameter	diameter	NOUN
cet-1009	26	34	of	of	ADP
cet-1009	26	35	rats	rat	NOUN
cet-1009	26	36	1262	1262	NUM
cet-1009	26	37	0	0	NUM
cet-1009	26	38	model	model	NOUN
cet-1009	26	39	control	control	PROPN
cet-1009	26	40	biminkang	biminkang	PROPN
cet-1009	26	41	low	low	PROPN
cet-1009	26	42	biminkang	biminkang	PROPN
cet-1009	26	43	middle	middle	PROPN
cet-1009	26	44	biminkang	biminkang	PROPN
cet-1009	26	45	high	high	ADJ
cet-1009	26	46	loratadine	loratadine	NOUN
cet-1009	27	1	o	o	PROPN
cet-1009	27	2	d	d	ADP
cet-1009	27	3	61	61	NUM
cet-1009	27	4	0	0	NUM
cet-1009	27	5	va	va	NOUN
cet-1009	27	6	lu	lu	PROPN
cet-1009	27	7	e	e	PROPN
cet-1009	27	8	0.02	0.02	NUM
cet-1009	27	9	0.04	0.04	NUM
cet-1009	27	10	0.06	0.06	NUM
cet-1009	27	11	0.08	0.08	NUM
cet-1009	27	12	0.10	0.10	NUM
cet-1009	27	13	0.12	0.12	NUM
cet-1009	27	14	0.14	0.14	NUM
cet-1009	27	15	figure	figure	NOUN
cet-1009	27	16	3	3	NUM
cet-1009	27	17	:	:	PUNCT
cet-1009	27	18	impact	impact	NOUN
cet-1009	27	19	of	of	ADP
cet-1009	27	20	different	different	ADJ
cet-1009	27	21	doses	dose	NOUN
cet-1009	27	22	of	of	ADP
cet-1009	27	23	biminkang	biminkang	NOUN
cet-1009	27	24	on	on	ADP
cet-1009	27	25	the	the	DET
cet-1009	27	26	od610	od610	ADJ
cet-1009	27	27	value	value	NOUN
cet-1009	27	28	of	of	ADP
cet-1009	27	29	rats	rat	NOUN
cet-1009	27	30	figure	figure	VERB
cet-1009	27	31	2	2	NUM
cet-1009	27	32	shows	show	VERB
cet-1009	27	33	the	the	DET
cet-1009	27	34	different	different	ADJ
cet-1009	27	35	doses	dose	NOUN
cet-1009	27	36	of	of	ADP
cet-1009	27	37	biminkang	biminkang	NOUN
cet-1009	27	38	on	on	ADP
cet-1009	27	39	the	the	DET
cet-1009	27	40	skin	skin	NOUN
cet-1009	27	41	locus	locus	NOUN
cet-1009	27	42	coeruleus	coeruleus	NOUN
cet-1009	27	43	diameter	diameter	NOUN
cet-1009	27	44	and	and	CCONJ
cet-1009	27	45	od610	od610	ADJ
cet-1009	27	46	value	value	NOUN
cet-1009	27	47	.	.	PUNCT
cet-1009	28	1	as	as	SCONJ
cet-1009	28	2	can	can	AUX
cet-1009	28	3	be	be	AUX
cet-1009	28	4	seen	see	VERB
cet-1009	28	5	from	from	ADP
cet-1009	28	6	the	the	DET
cet-1009	28	7	figure	figure	NOUN
cet-1009	28	8	,	,	PUNCT
cet-1009	28	9	the	the	PRON
cet-1009	28	10	higher	high	ADJ
cet-1009	28	11	the	the	DET
cet-1009	28	12	dose	dose	NOUN
cet-1009	28	13	of	of	ADP
cet-1009	28	14	biminkang	biminkang	NOUN
cet-1009	28	15	,	,	PUNCT
cet-1009	28	16	the	the	PRON
cet-1009	28	17	smaller	small	ADJ
cet-1009	28	18	the	the	DET
cet-1009	28	19	skin	skin	NOUN
cet-1009	28	20	locus	locus	NOUN
cet-1009	28	21	coeruleus	coeruleus	NOUN
cet-1009	28	22	diameter	diameter	NOUN
cet-1009	28	23	of	of	ADP
cet-1009	28	24	rats	rat	NOUN
cet-1009	28	25	and	and	CCONJ
cet-1009	28	26	the	the	DET
cet-1009	28	27	smaller	small	ADJ
cet-1009	28	28	the	the	DET
cet-1009	28	29	value	value	NOUN
cet-1009	28	30	of	of	ADP
cet-1009	28	31	od610	od610	PROPN
cet-1009	28	32	.	.	PUNCT
cet-1009	29	1	the	the	DET
cet-1009	29	2	pharmacological	pharmacological	ADJ
cet-1009	29	3	effect	effect	NOUN
cet-1009	29	4	of	of	ADP
cet-1009	29	5	10.0mg	10.0mg	NUM
cet-1009	29	6	/	/	SYM
cet-1009	29	7	ml	ml	X
cet-1009	29	8	of	of	ADP
cet-1009	29	9	high	high	ADJ
cet-1009	29	10	-	-	PUNCT
cet-1009	29	11	dose	dose	NOUN
cet-1009	29	12	group	group	NOUN
cet-1009	29	13	is	be	AUX
cet-1009	29	14	basically	basically	ADV
cet-1009	29	15	the	the	DET
cet-1009	29	16	same	same	ADJ
cet-1009	29	17	as	as	ADP
cet-1009	29	18	the	the	DET
cet-1009	29	19	effect	effect	NOUN
cet-1009	29	20	of	of	ADP
cet-1009	29	21	loratadine	loratadine	NOUN
cet-1009	29	22	.	.	PUNCT
cet-1009	30	1	the	the	DET
cet-1009	30	2	ileum	ileum	NOUN
cet-1009	30	3	,	,	PUNCT
cet-1009	30	4	under	under	ADP
cet-1009	30	5	the	the	DET
cet-1009	30	6	action	action	NOUN
cet-1009	30	7	of	of	ADP
cet-1009	30	8	different	different	ADJ
cet-1009	30	9	antigens	antigen	NOUN
cet-1009	30	10	,	,	PUNCT
cet-1009	30	11	will	will	AUX
cet-1009	30	12	releases	release	VERB
cet-1009	30	13	the	the	DET
cet-1009	30	14	source	source	NOUN
cet-1009	30	15	medium	medium	NOUN
cet-1009	30	16	that	that	PRON
cet-1009	30	17	causes	cause	VERB
cet-1009	30	18	allergy	allergy	NOUN
cet-1009	30	19	of	of	ADP
cet-1009	30	20	rats	rat	NOUN
cet-1009	30	21	,	,	PUNCT
cet-1009	30	22	resulting	result	VERB
cet-1009	30	23	in	in	ADP
cet-1009	30	24	the	the	DET
cet-1009	30	25	contraction	contraction	NOUN
cet-1009	30	26	of	of	ADP
cet-1009	30	27	smooth	smooth	ADJ
cet-1009	30	28	muscle	muscle	NOUN
cet-1009	30	29	of	of	ADP
cet-1009	30	30	the	the	DET
cet-1009	30	31	ileum	ileum	NOUN
cet-1009	30	32	.	.	PUNCT
cet-1009	31	1	after	after	ADP
cet-1009	31	2	dosing	dose	VERB
cet-1009	31	3	,	,	PUNCT
cet-1009	31	4	inhibition	inhibition	NOUN
cet-1009	31	5	effect	effect	NOUN
cet-1009	31	6	on	on	ADP
cet-1009	31	7	the	the	DET
cet-1009	31	8	contraction	contraction	NOUN
cet-1009	31	9	of	of	ADP
cet-1009	31	10	the	the	DET
cet-1009	31	11	ileum	ileum	NOUN
cet-1009	31	12	proves	prove	VERB
cet-1009	31	13	that	that	SCONJ
cet-1009	31	14	the	the	DET
cet-1009	31	15	medicine	medicine	NOUN
cet-1009	31	16	has	have	VERB
cet-1009	31	17	an	an	DET
cet-1009	31	18	anti	anti	ADJ
cet-1009	31	19	-	-	ADJ
cet-1009	31	20	hypersensitivity	hypersensitivity	ADJ
cet-1009	31	21	effect	effect	NOUN
cet-1009	31	22	.	.	PUNCT
cet-1009	32	1	the	the	DET
cet-1009	32	2	results	result	NOUN
cet-1009	32	3	from	from	ADP
cet-1009	32	4	figure	figure	NOUN
cet-1009	32	5	1	1	NUM
cet-1009	32	6	show	show	VERB
cet-1009	32	7	that	that	SCONJ
cet-1009	32	8	biminkang	biminkang	PROPN
cet-1009	32	9	has	have	VERB
cet-1009	32	10	a	a	DET
cet-1009	32	11	good	good	ADJ
cet-1009	32	12	inhibitory	inhibitory	ADJ
cet-1009	32	13	effect	effect	NOUN
cet-1009	32	14	on	on	ADP
cet-1009	32	15	the	the	DET
cet-1009	32	16	allergic	allergic	ADJ
cet-1009	32	17	contraction	contraction	NOUN
cet-1009	32	18	of	of	ADP
cet-1009	32	19	rats	rat	NOUN
cet-1009	32	20	.	.	PUNCT
cet-1009	33	1	at	at	ADP
cet-1009	33	2	a	a	DET
cet-1009	33	3	certain	certain	ADJ
cet-1009	33	4	dose	dose	NOUN
cet-1009	33	5	,	,	PUNCT
cet-1009	33	6	the	the	PRON
cet-1009	33	7	higher	high	ADJ
cet-1009	33	8	the	the	DET
cet-1009	33	9	bimikang	bimikang	PROPN
cet-1009	33	10	content	content	PROPN
cet-1009	33	11	,	,	PUNCT
cet-1009	33	12	the	the	PRON
cet-1009	33	13	better	well	ADJ
cet-1009	33	14	the	the	DET
cet-1009	33	15	inhibitory	inhibitory	ADJ
cet-1009	33	16	effect	effect	NOUN
cet-1009	33	17	on	on	ADP
cet-1009	33	18	allergic	allergic	ADJ
cet-1009	33	19	contraction	contraction	NOUN
cet-1009	33	20	.	.	PUNCT
cet-1009	34	1	histamine	histamine	NOUN
cet-1009	34	2	is	be	AUX
cet-1009	34	3	the	the	DET
cet-1009	34	4	main	main	ADJ
cet-1009	34	5	cause	cause	NOUN
cet-1009	34	6	of	of	ADP
cet-1009	34	7	allergic	allergic	ADJ
cet-1009	34	8	rhinitis	rhinitis	NOUN
cet-1009	34	9	,	,	PUNCT
cet-1009	34	10	and	and	CCONJ
cet-1009	34	11	the	the	DET
cet-1009	34	12	presence	presence	NOUN
cet-1009	34	13	of	of	ADP
cet-1009	34	14	histamine	histamine	NOUN
cet-1009	34	15	will	will	AUX
cet-1009	34	16	lead	lead	VERB
cet-1009	34	17	to	to	ADP
cet-1009	34	18	the	the	DET
cet-1009	34	19	smooth	smooth	ADJ
cet-1009	34	20	muscle	muscle	NOUN
cet-1009	34	21	spasm	spasm	NOUN
cet-1009	34	22	and	and	CCONJ
cet-1009	34	23	increase	increase	VERB
cet-1009	34	24	in	in	ADP
cet-1009	34	25	vascular	vascular	ADJ
cet-1009	34	26	permeability	permeability	NOUN
cet-1009	34	27	.	.	PUNCT
cet-1009	35	1	the	the	DET
cet-1009	35	2	results	result	NOUN
cet-1009	35	3	of	of	ADP
cet-1009	35	4	the	the	DET
cet-1009	35	5	test	test	NOUN
cet-1009	35	6	in	in	ADP
cet-1009	35	7	figure	figure	NOUN
cet-1009	35	8	2	2	NUM
cet-1009	35	9	and	and	CCONJ
cet-1009	35	10	3	3	NUM
cet-1009	35	11	indicate	indicate	VERB
cet-1009	35	12	that	that	SCONJ
cet-1009	35	13	biminkang	biminkang	NOUN
cet-1009	35	14	can	can	AUX
cet-1009	35	15	inhibit	inhibit	VERB
cet-1009	35	16	the	the	DET
cet-1009	35	17	hemangiectasis	hemangiectasis	NOUN
cet-1009	35	18	caused	cause	VERB
cet-1009	35	19	by	by	ADP
cet-1009	35	20	histamine	histamine	NOUN
cet-1009	35	21	and	and	CCONJ
cet-1009	35	22	reduce	reduce	VERB
cet-1009	35	23	the	the	DET
cet-1009	35	24	od610	od610	ADJ
cet-1009	35	25	value	value	NOUN
cet-1009	35	26	.	.	PUNCT
cet-1009	36	1	3	3	X
cet-1009	36	2	.	.	PUNCT
cet-1009	36	3	immunopharmacological	immunopharmacological	ADJ
cet-1009	36	4	effects	effect	NOUN
cet-1009	36	5	analysis	analysis	NOUN
cet-1009	36	6	of	of	ADP
cet-1009	36	7	anti	anti	ADJ
cet-1009	36	8	-	-	ADJ
cet-1009	36	9	rhinitis	rhinitis	ADJ
cet-1009	36	10	medicine	medicine	NOUN
cet-1009	36	11	mc	mc	PROPN
cet-1009	36	12	number	number	PROPN
cet-1009	36	13	,	,	PUNCT
cet-1009	36	14	eos	eos	PROPN
cet-1009	36	15	,	,	PUNCT
cet-1009	36	16	sp	sp	ADP
cet-1009	36	17	and	and	CCONJ
cet-1009	36	18	lge	lge	PROPN
cet-1009	36	19	are	be	AUX
cet-1009	36	20	four	four	NUM
cet-1009	36	21	important	important	ADJ
cet-1009	36	22	parameters	parameter	NOUN
cet-1009	36	23	of	of	ADP
cet-1009	36	24	allergic	allergic	ADJ
cet-1009	36	25	rhinitis	rhinitis	NOUN
cet-1009	36	26	characterization	characterization	NOUN
cet-1009	36	27	and	and	CCONJ
cet-1009	36	28	these	these	DET
cet-1009	36	29	four	four	NUM
cet-1009	36	30	parameters	parameter	NOUN
cet-1009	36	31	will	will	AUX
cet-1009	36	32	be	be	AUX
cet-1009	36	33	analyzed	analyze	VERB
cet-1009	36	34	in	in	ADP
cet-1009	36	35	the	the	DET
cet-1009	36	36	following	following	ADJ
cet-1009	36	37	part	part	NOUN
cet-1009	36	38	.	.	PUNCT
cet-1009	37	1	table	table	NOUN
cet-1009	37	2	1	1	NUM
cet-1009	37	3	shows	show	VERB
cet-1009	37	4	the	the	DET
cet-1009	37	5	biological	biological	ADJ
cet-1009	37	6	emergent	emergent	NOUN
cet-1009	37	7	symptom	symptom	NOUN
cet-1009	37	8	of	of	ADP
cet-1009	37	9	different	different	ADJ
cet-1009	37	10	groups	group	NOUN
cet-1009	37	11	of	of	ADP
cet-1009	37	12	rats	rat	NOUN
cet-1009	37	13	after	after	ADP
cet-1009	37	14	antigen	antigen	ADJ
cet-1009	37	15	invasion	invasion	NOUN
cet-1009	37	16	(	(	PUNCT
cet-1009	37	17	because	because	SCONJ
cet-1009	37	18	of	of	ADP
cet-1009	37	19	no	no	DET
cet-1009	37	20	antigen	antigen	NOUN
cet-1009	37	21	in	in	ADP
cet-1009	37	22	the	the	DET
cet-1009	37	23	blank	blank	PROPN
cet-1009	37	24	control	control	PROPN
cet-1009	37	25	group	group	NOUN
cet-1009	37	26	,	,	PUNCT
cet-1009	37	27	no	no	DET
cet-1009	37	28	emergent	emergent	ADJ
cet-1009	37	29	symptom	symptom	NOUN
cet-1009	37	30	of	of	ADP
cet-1009	37	31	rhinitis	rhinitis	NOUN
cet-1009	37	32	)	)	PUNCT
cet-1009	37	33	.	.	PUNCT
cet-1009	38	1	the	the	DET
cet-1009	38	2	model	model	PROPN
cet-1009	38	3	control	control	PROPN
cet-1009	38	4	group	group	PROPN
cet-1009	38	5	is	be	AUX
cet-1009	38	6	the	the	DET
cet-1009	38	7	group	group	NOUN
cet-1009	38	8	without	without	ADP
cet-1009	38	9	dosing	dose	VERB
cet-1009	38	10	and	and	CCONJ
cet-1009	38	11	the	the	DET
cet-1009	38	12	dosing	dosing	NOUN
cet-1009	38	13	in	in	ADP
cet-1009	38	14	the	the	DET
cet-1009	38	15	remaining	remain	VERB
cet-1009	38	16	three	three	NUM
cet-1009	38	17	groups	group	NOUN
cet-1009	38	18	is	be	AUX
cet-1009	38	19	biminkang	biminkang	ADJ
cet-1009	38	20	,	,	PUNCT
cet-1009	38	21	xinqin	xinqin	PROPN
cet-1009	38	22	granules	granule	NOUN
cet-1009	38	23	and	and	CCONJ
cet-1009	38	24	loratadine	loratadine	NOUN
cet-1009	38	25	respectively	respectively	ADV
cet-1009	38	26	.	.	PUNCT
cet-1009	39	1	it	it	PRON
cet-1009	39	2	can	can	AUX
cet-1009	39	3	be	be	AUX
cet-1009	39	4	seen	see	VERB
cet-1009	39	5	from	from	ADP
cet-1009	39	6	the	the	DET
cet-1009	39	7	table	table	NOUN
cet-1009	39	8	that	that	SCONJ
cet-1009	39	9	after	after	ADP
cet-1009	39	10	dosing	dose	VERB
cet-1009	39	11	of	of	ADP
cet-1009	39	12	biminkang	biminkang	NOUN
cet-1009	39	13	,	,	PUNCT
cet-1009	39	14	the	the	DET
cet-1009	39	15	symptom	symptom	NOUN
cet-1009	39	16	score	score	NOUN
cet-1009	39	17	is	be	AUX
cet-1009	39	18	significantly	significantly	ADV
cet-1009	39	19	lower	low	ADJ
cet-1009	39	20	than	than	ADP
cet-1009	39	21	that	that	PRON
cet-1009	39	22	of	of	ADP
cet-1009	39	23	model	model	PROPN
cet-1009	39	24	control	control	PROPN
cet-1009	39	25	group	group	PROPN
cet-1009	39	26	and	and	CCONJ
cet-1009	39	27	xinqin	xinqin	PROPN
cet-1009	39	28	granule	granule	PROPN
cet-1009	39	29	group	group	NOUN
cet-1009	39	30	,	,	PUNCT
cet-1009	39	31	but	but	CCONJ
cet-1009	39	32	the	the	DET
cet-1009	39	33	symptom	symptom	NOUN
cet-1009	39	34	score	score	NOUN
cet-1009	39	35	is	be	AUX
cet-1009	39	36	higher	high	ADJ
cet-1009	39	37	than	than	ADP
cet-1009	39	38	that	that	PRON
cet-1009	39	39	of	of	ADP
cet-1009	39	40	loratadine	loratadine	PROPN
cet-1009	39	41	group	group	NOUN
cet-1009	39	42	.	.	PUNCT
cet-1009	40	1	table	table	NOUN
cet-1009	40	2	1	1	NUM
cet-1009	40	3	:	:	PUNCT
cet-1009	40	4	impact	impact	NOUN
cet-1009	40	5	of	of	ADP
cet-1009	40	6	different	different	ADJ
cet-1009	40	7	anti	anti	ADJ
cet-1009	40	8	-	-	ADJ
cet-1009	40	9	rhinitis	rhinitis	ADJ
cet-1009	40	10	medicine	medicine	NOUN
cet-1009	40	11	on	on	ADP
cet-1009	40	12	running	run	VERB
cet-1009	40	13	nose	nose	NOUN
cet-1009	40	14	and	and	CCONJ
cet-1009	40	15	scratching	scratching	NOUN
cet-1009	40	16	nose	nose	PROPN
cet-1009	40	17	group	group	PROPN
cet-1009	40	18	reciprocal	reciprocal	PROPN
cet-1009	40	19	dose	dose	PROPN
cet-1009	40	20	symptom	symptom	NOUN
cet-1009	40	21	score	score	PROPN
cet-1009	40	22	blank	blank	PROPN
cet-1009	40	23	control	control	NOUN
cet-1009	40	24	8	8	NUM
cet-1009	40	25	normal	normal	ADJ
cet-1009	40	26	saline	saline	NOUN
cet-1009	40	27	0	0	NUM
cet-1009	40	28	model	model	NOUN
cet-1009	40	29	control	control	NOUN
cet-1009	40	30	8	8	NUM
cet-1009	40	31	normal	normal	ADJ
cet-1009	40	32	saline	saline	NOUN
cet-1009	40	33	6.98±0.57	6.98±0.57	PROPN
cet-1009	40	34	biminkang	biminkang	NOUN
cet-1009	40	35	8	8	NUM
cet-1009	40	36	4.9	4.9	NUM
cet-1009	40	37	2.31±0.29	2.31±0.29	NUM
cet-1009	41	1	xinqin	xinqin	NOUN
cet-1009	41	2	granule	granule	NOUN
cet-1009	41	3	8	8	NUM
cet-1009	41	4	4.9	4.9	NUM
cet-1009	41	5	3.20±0.56	3.20±0.56	NUM
cet-1009	41	6	loratadine	loratadine	NOUN
cet-1009	41	7	8	8	NUM
cet-1009	41	8	0.002	0.002	NUM
cet-1009	41	9	1.85±0.33	1.85±0.33	NUM
cet-1009	41	10	1263	1263	NUM
cet-1009	41	11	figure	figure	NOUN
cet-1009	41	12	4	4	NUM
cet-1009	41	13	shows	show	VERB
cet-1009	41	14	the	the	DET
cet-1009	41	15	impact	impact	NOUN
cet-1009	41	16	of	of	ADP
cet-1009	41	17	different	different	ADJ
cet-1009	41	18	groups	group	NOUN
cet-1009	41	19	of	of	ADP
cet-1009	41	20	anti	anti	ADJ
cet-1009	41	21	-	-	ADJ
cet-1009	41	22	rhinitis	rhinitis	ADJ
cet-1009	41	23	medicine	medicine	NOUN
cet-1009	41	24	on	on	ADP
cet-1009	41	25	the	the	DET
cet-1009	41	26	nasal	nasal	PROPN
cet-1009	41	27	secreta	secreta	PROPN
cet-1009	41	28	and	and	CCONJ
cet-1009	41	29	mucosal	mucosal	ADJ
cet-1009	41	30	eoc	eoc	NOUN
cet-1009	41	31	of	of	ADP
cet-1009	41	32	rats	rat	NOUN
cet-1009	41	33	.	.	PUNCT
cet-1009	42	1	as	as	SCONJ
cet-1009	42	2	can	can	AUX
cet-1009	42	3	be	be	AUX
cet-1009	42	4	seen	see	VERB
cet-1009	42	5	from	from	ADP
cet-1009	42	6	the	the	DET
cet-1009	42	7	figure	figure	NOUN
cet-1009	42	8	,	,	PUNCT
cet-1009	42	9	the	the	DET
cet-1009	42	10	eos	eos	PROPN
cet-1009	42	11	number	number	NOUN
cet-1009	42	12	of	of	ADP
cet-1009	42	13	the	the	DET
cet-1009	42	14	nasal	nasal	PROPN
cet-1009	42	15	secreta	secreta	PROPN
cet-1009	42	16	and	and	CCONJ
cet-1009	42	17	nasal	nasal	PROPN
cet-1009	42	18	mucosal	mucosal	NOUN
cet-1009	42	19	of	of	ADP
cet-1009	42	20	the	the	DET
cet-1009	42	21	model	model	PROPN
cet-1009	42	22	control	control	PROPN
cet-1009	42	23	group	group	PROPN
cet-1009	42	24	is	be	AUX
cet-1009	42	25	the	the	DET
cet-1009	42	26	largest	large	ADJ
cet-1009	42	27	.	.	PUNCT
cet-1009	43	1	the	the	DET
cet-1009	43	2	number	number	NOUN
cet-1009	43	3	of	of	ADP
cet-1009	43	4	eos	eos	PROPN
cet-1009	43	5	of	of	ADP
cet-1009	43	6	the	the	DET
cet-1009	43	7	infected	infect	VERB
cet-1009	43	8	rats	rat	NOUN
cet-1009	43	9	decreases	decrease	VERB
cet-1009	43	10	slightly	slightly	ADV
cet-1009	43	11	after	after	ADP
cet-1009	43	12	the	the	DET
cet-1009	43	13	dosing	dosing	NOUN
cet-1009	43	14	of	of	ADP
cet-1009	43	15	xinqin	xinqin	PROPN
cet-1009	43	16	granules	granule	NOUN
cet-1009	43	17	;	;	PUNCT
cet-1009	43	18	the	the	DET
cet-1009	43	19	decrease	decrease	NOUN
cet-1009	43	20	of	of	ADP
cet-1009	43	21	eos	eos	PROPN
cet-1009	43	22	after	after	ADP
cet-1009	43	23	the	the	DET
cet-1009	43	24	dosing	dosing	NOUN
cet-1009	43	25	of	of	ADP
cet-1009	43	26	biminkang	biminkang	NOUN
cet-1009	43	27	and	and	CCONJ
cet-1009	43	28	loratadine	loratadine	NOUN
cet-1009	43	29	is	be	AUX
cet-1009	43	30	significant	significant	ADJ
cet-1009	43	31	,	,	PUNCT
cet-1009	43	32	and	and	CCONJ
cet-1009	43	33	there	there	PRON
cet-1009	43	34	was	be	VERB
cet-1009	43	35	no	no	DET
cet-1009	43	36	significant	significant	ADJ
cet-1009	43	37	difference	difference	NOUN
cet-1009	43	38	between	between	ADP
cet-1009	43	39	these	these	DET
cet-1009	43	40	two	two	NUM
cet-1009	43	41	.	.	PUNCT
cet-1009	43	42	0	0	NUM
cet-1009	44	1	blank	blank	PROPN
cet-1009	44	2	control	control	PROPN
cet-1009	44	3	loratadine	loratadine	NOUN
cet-1009	44	4	16	16	NUM
cet-1009	44	5	10	10	NUM
cet-1009	44	6	12	12	NUM
cet-1009	44	7	14	14	NUM
cet-1009	44	8	8	8	NUM
cet-1009	44	9	6	6	NUM
cet-1009	44	10	4	4	NUM
cet-1009	44	11	2	2	NUM
cet-1009	44	12	eo	eo	NOUN
cet-1009	44	13	s	s	PROPN
cet-1009	44	14	biminkang	biminkang	PROPN
cet-1009	44	15	xinqin	xinqin	PROPN
cet-1009	44	16	granulemodel	granulemodel	PROPN
cet-1009	44	17	control	control	PROPN
cet-1009	44	18	figure	figure	NOUN
cet-1009	44	19	4	4	NUM
cet-1009	44	20	:	:	PUNCT
cet-1009	44	21	impact	impact	NOUN
cet-1009	44	22	of	of	ADP
cet-1009	44	23	different	different	ADJ
cet-1009	44	24	groups	group	NOUN
cet-1009	44	25	of	of	ADP
cet-1009	44	26	anti	anti	ADJ
cet-1009	44	27	-	-	ADJ
cet-1009	44	28	rhinitis	rhinitis	ADJ
cet-1009	44	29	medicine	medicine	NOUN
cet-1009	44	30	on	on	ADP
cet-1009	44	31	the	the	DET
cet-1009	44	32	nasal	nasal	PROPN
cet-1009	44	33	secreta	secreta	PROPN
cet-1009	44	34	and	and	CCONJ
cet-1009	44	35	mucosal	mucosal	ADJ
cet-1009	44	36	eoc	eoc	NOUN
cet-1009	44	37	of	of	ADP
cet-1009	44	38	rats	rat	NOUN
cet-1009	44	39	0	0	NUM
cet-1009	44	40	blank	blank	PROPN
cet-1009	44	41	control	control	PROPN
cet-1009	44	42	biminkang	biminkang	PROPN
cet-1009	44	43	loratadinexinqin	loratadinexinqin	PROPN
cet-1009	44	44	granulemodel	granulemodel	PROPN
cet-1009	44	45	control	control	PROPN
cet-1009	44	46	12	12	NUM
cet-1009	44	47	10	10	NUM
cet-1009	44	48	8	8	NUM
cet-1009	44	49	6	6	NUM
cet-1009	44	50	4	4	NUM
cet-1009	44	51	2	2	NUM
cet-1009	44	52	m	m	NOUN
cet-1009	44	53	c	c	NOUN
cet-1009	44	54	figure	figure	NOUN
cet-1009	44	55	5	5	NUM
cet-1009	44	56	:	:	PUNCT
cet-1009	44	57	impact	impact	NOUN
cet-1009	44	58	of	of	ADP
cet-1009	44	59	different	different	ADJ
cet-1009	44	60	groups	group	NOUN
cet-1009	44	61	of	of	ADP
cet-1009	44	62	anti	anti	ADJ
cet-1009	44	63	-	-	ADJ
cet-1009	44	64	rhinitis	rhinitis	ADJ
cet-1009	44	65	medicine	medicine	NOUN
cet-1009	44	66	on	on	ADP
cet-1009	44	67	the	the	DET
cet-1009	44	68	nasal	nasal	ADJ
cet-1009	44	69	excitation	excitation	NOUN
cet-1009	44	70	mc	mc	PROPN
cet-1009	44	71	number	number	NOUN
cet-1009	44	72	of	of	ADP
cet-1009	44	73	rats	rat	NOUN
cet-1009	44	74	0	0	NUM
cet-1009	44	75	blank	blank	PROPN
cet-1009	44	76	control	control	PROPN
cet-1009	44	77	biminkang	biminkang	PROPN
cet-1009	44	78	loratadinexinqin	loratadinexinqin	PROPN
cet-1009	44	79	granulemodel	granulemodel	PROPN
cet-1009	44	80	control	control	NOUN
cet-1009	44	81	20	20	NUM
cet-1009	44	82	40	40	NUM
cet-1009	44	83	60	60	NUM
cet-1009	44	84	80	80	NUM
cet-1009	44	85	100	100	NUM
cet-1009	44	86	160	160	NUM
cet-1009	44	87	140	140	NUM
cet-1009	44	88	120	120	NUM
cet-1009	44	89	sp	sp	NOUN
cet-1009	44	90	(	(	PUNCT
cet-1009	44	91	p	p	NOUN
cet-1009	44	92	g/	g/	NOUN
cet-1009	44	93	m	m	NOUN
cet-1009	44	94	l	l	NOUN
cet-1009	44	95	/	/	SYM
cet-1009	44	96	m	m	PROPN
cet-1009	44	97	g	g	NOUN
cet-1009	44	98	)	)	PUNCT
cet-1009	44	99	figure	figure	NOUN
cet-1009	44	100	6	6	NUM
cet-1009	44	101	:	:	PUNCT
cet-1009	44	102	impact	impact	NOUN
cet-1009	44	103	of	of	ADP
cet-1009	44	104	different	different	ADJ
cet-1009	44	105	groups	group	NOUN
cet-1009	44	106	of	of	ADP
cet-1009	44	107	anti	anti	ADJ
cet-1009	44	108	-	-	ADJ
cet-1009	44	109	rhinitis	rhinitis	ADJ
cet-1009	44	110	medicine	medicine	NOUN
cet-1009	44	111	on	on	ADP
cet-1009	44	112	the	the	DET
cet-1009	44	113	nasal	nasal	NOUN
cet-1009	44	114	mucosal	mucosal	NOUN
cet-1009	44	115	sp	sp	NOUN
cet-1009	44	116	of	of	ADP
cet-1009	44	117	rats	rat	NOUN
cet-1009	44	118	1264	1264	NUM
cet-1009	44	119	figure	figure	NOUN
cet-1009	44	120	5	5	NUM
cet-1009	44	121	and	and	CCONJ
cet-1009	44	122	figure	figure	VERB
cet-1009	44	123	6	6	NUM
cet-1009	44	124	show	show	VERB
cet-1009	44	125	the	the	DET
cet-1009	44	126	different	different	ADJ
cet-1009	44	127	groups	group	NOUN
cet-1009	44	128	of	of	ADP
cet-1009	44	129	anti	anti	ADJ
cet-1009	44	130	-	-	ADJ
cet-1009	44	131	rhinitis	rhinitis	ADJ
cet-1009	44	132	medicine	medicine	NOUN
cet-1009	44	133	on	on	ADP
cet-1009	44	134	the	the	DET
cet-1009	44	135	number	number	NOUN
cet-1009	44	136	of	of	ADP
cet-1009	44	137	nasal	nasal	ADJ
cet-1009	44	138	excitation	excitation	NOUN
cet-1009	44	139	mc	mc	PROPN
cet-1009	44	140	and	and	CCONJ
cet-1009	44	141	nasal	nasal	PROPN
cet-1009	44	142	mucosa	mucosa	PROPN
cet-1009	44	143	sp	sp	PROPN
cet-1009	44	144	.	.	PUNCT
cet-1009	45	1	as	as	SCONJ
cet-1009	45	2	can	can	AUX
cet-1009	45	3	be	be	AUX
cet-1009	45	4	seen	see	VERB
cet-1009	45	5	from	from	ADP
cet-1009	45	6	the	the	DET
cet-1009	45	7	figure	figure	NOUN
cet-1009	45	8	,	,	PUNCT
cet-1009	45	9	the	the	DET
cet-1009	45	10	number	number	NOUN
cet-1009	45	11	of	of	ADP
cet-1009	45	12	excitation	excitation	NOUN
cet-1009	45	13	mc	mc	PROPN
cet-1009	45	14	in	in	ADP
cet-1009	45	15	the	the	DET
cet-1009	45	16	model	model	NOUN
cet-1009	45	17	control	control	PROPN
cet-1009	45	18	group	group	NOUN
cet-1009	45	19	is	be	AUX
cet-1009	45	20	much	much	ADV
cet-1009	45	21	higher	high	ADJ
cet-1009	45	22	than	than	ADP
cet-1009	45	23	that	that	PRON
cet-1009	45	24	in	in	ADP
cet-1009	45	25	the	the	DET
cet-1009	45	26	blank	blank	PROPN
cet-1009	45	27	control	control	PROPN
cet-1009	45	28	group	group	NOUN
cet-1009	45	29	and	and	CCONJ
cet-1009	45	30	different	different	ADJ
cet-1009	45	31	dosing	dose	VERB
cet-1009	45	32	groups	group	NOUN
cet-1009	45	33	,	,	PUNCT
cet-1009	45	34	and	and	CCONJ
cet-1009	45	35	there	there	PRON
cet-1009	45	36	is	be	VERB
cet-1009	45	37	no	no	DET
cet-1009	45	38	significant	significant	ADJ
cet-1009	45	39	difference	difference	NOUN
cet-1009	45	40	in	in	ADP
cet-1009	45	41	the	the	DET
cet-1009	45	42	number	number	NOUN
cet-1009	45	43	of	of	ADP
cet-1009	45	44	excitation	excitation	NOUN
cet-1009	45	45	mc	mc	PROPN
cet-1009	45	46	between	between	ADP
cet-1009	45	47	the	the	DET
cet-1009	45	48	three	three	NUM
cet-1009	45	49	dosing	dose	VERB
cet-1009	45	50	groups	group	NOUN
cet-1009	45	51	of	of	ADP
cet-1009	45	52	bimincome	bimincome	NOUN
cet-1009	45	53	,	,	PUNCT
cet-1009	45	54	xinqin	xinqin	NOUN
cet-1009	45	55	granules	granule	NOUN
cet-1009	45	56	and	and	CCONJ
cet-1009	45	57	loratadine	loratadine	NOUN
cet-1009	45	58	.	.	PUNCT
cet-1009	46	1	figure	figure	NOUN
cet-1009	46	2	7	7	NUM
cet-1009	46	3	shows	show	VERB
cet-1009	46	4	the	the	DET
cet-1009	46	5	impact	impact	NOUN
cet-1009	46	6	of	of	ADP
cet-1009	46	7	different	different	ADJ
cet-1009	46	8	groups	group	NOUN
cet-1009	46	9	of	of	ADP
cet-1009	46	10	anti	anti	ADJ
cet-1009	46	11	-	-	ADJ
cet-1009	46	12	rhinitis	rhinitis	ADJ
cet-1009	46	13	medicine	medicine	NOUN
cet-1009	46	14	on	on	ADP
cet-1009	46	15	the	the	DET
cet-1009	46	16	lge	lge	NOUN
cet-1009	46	17	(	(	PUNCT
cet-1009	46	18	u	u	NOUN
cet-1009	46	19	/	/	SYM
cet-1009	46	20	ml	ml	NOUN
cet-1009	46	21	)	)	PUNCT
cet-1009	46	22	of	of	ADP
cet-1009	46	23	rats	rat	NOUN
cet-1009	46	24	.	.	PUNCT
cet-1009	47	1	as	as	SCONJ
cet-1009	47	2	can	can	AUX
cet-1009	47	3	be	be	AUX
cet-1009	47	4	seen	see	VERB
cet-1009	47	5	from	from	ADP
cet-1009	47	6	the	the	DET
cet-1009	47	7	figure	figure	NOUN
cet-1009	47	8	,	,	PUNCT
cet-1009	47	9	the	the	DET
cet-1009	47	10	ige	ige	PROPN
cet-1009	47	11	(	(	PUNCT
cet-1009	47	12	u	u	NOUN
cet-1009	47	13	/	/	SYM
cet-1009	47	14	ml	ml	NOUN
cet-1009	47	15	)	)	PUNCT
cet-1009	47	16	content	content	NOUN
cet-1009	47	17	of	of	ADP
cet-1009	47	18	rats	rat	NOUN
cet-1009	47	19	after	after	ADP
cet-1009	47	20	the	the	DET
cet-1009	47	21	dosing	dosing	NOUN
cet-1009	47	22	of	of	ADP
cet-1009	47	23	biminkang	biminkang	NOUN
cet-1009	47	24	is	be	AUX
cet-1009	47	25	significantly	significantly	ADV
cet-1009	47	26	lower	low	ADJ
cet-1009	47	27	than	than	ADP
cet-1009	47	28	that	that	PRON
cet-1009	47	29	of	of	ADP
cet-1009	47	30	the	the	DET
cet-1009	47	31	model	model	PROPN
cet-1009	47	32	control	control	PROPN
cet-1009	47	33	group	group	PROPN
cet-1009	47	34	,	,	PUNCT
cet-1009	47	35	xinqin	xinqin	PROPN
cet-1009	47	36	granules	granule	NOUN
cet-1009	47	37	and	and	CCONJ
cet-1009	47	38	loratadine	loratadine	NOUN
cet-1009	47	39	dosing	dose	VERB
cet-1009	47	40	group	group	NOUN
cet-1009	47	41	.	.	PUNCT
cet-1009	48	1	blank	blank	PROPN
cet-1009	48	2	control	control	PROPN
cet-1009	48	3	biminkang	biminkang	PROPN
cet-1009	48	4	loratadinexinqin	loratadinexinqin	PROPN
cet-1009	48	5	granulemodel	granulemodel	PROPN
cet-1009	48	6	control	control	NOUN
cet-1009	48	7	200	200	NUM
cet-1009	48	8	180	180	NUM
cet-1009	48	9	160	160	NUM
cet-1009	48	10	140	140	NUM
cet-1009	48	11	120	120	NUM
cet-1009	48	12	100	100	NUM
cet-1009	48	13	20	20	NUM
cet-1009	48	14	40	40	NUM
cet-1009	48	15	60	60	NUM
cet-1009	48	16	80	80	NUM
cet-1009	48	17	0	0	NUM
cet-1009	49	1	ig	ig	PROPN
cet-1009	49	2	e	e	PROPN
cet-1009	49	3	(	(	PUNCT
cet-1009	49	4	u	u	NOUN
cet-1009	49	5	/m	/m	NOUN
cet-1009	49	6	l	l	NOUN
cet-1009	49	7	)	)	PUNCT
cet-1009	49	8	figure	figure	NOUN
cet-1009	49	9	7	7	NUM
cet-1009	49	10	:	:	PUNCT
cet-1009	49	11	impact	impact	NOUN
cet-1009	49	12	of	of	ADP
cet-1009	49	13	different	different	ADJ
cet-1009	49	14	groups	group	NOUN
cet-1009	49	15	of	of	ADP
cet-1009	49	16	anti	anti	ADJ
cet-1009	49	17	-	-	ADJ
cet-1009	49	18	rhinitis	rhinitis	ADJ
cet-1009	49	19	medicine	medicine	NOUN
cet-1009	49	20	on	on	ADP
cet-1009	49	21	the	the	DET
cet-1009	49	22	lge(u	lge(u	PROPN
cet-1009	49	23	/	/	SYM
cet-1009	49	24	ml	ml	NOUN
cet-1009	49	25	)	)	PUNCT
cet-1009	49	26	of	of	ADP
cet-1009	49	27	rats	rat	NOUN
cet-1009	49	28	after	after	ADP
cet-1009	49	29	invasion	invasion	NOUN
cet-1009	49	30	of	of	ADP
cet-1009	49	31	various	various	ADJ
cet-1009	49	32	kinds	kind	NOUN
cet-1009	49	33	of	of	ADP
cet-1009	49	34	antigens	antigen	NOUN
cet-1009	49	35	,	,	PUNCT
cet-1009	49	36	running	running	NOUN
cet-1009	49	37	nose	nose	NOUN
cet-1009	49	38	,	,	PUNCT
cet-1009	49	39	scratching	scratching	NOUN
cet-1009	49	40	nose	nose	NOUN
cet-1009	49	41	and	and	CCONJ
cet-1009	49	42	other	other	ADJ
cet-1009	49	43	rhinitis	rhinitis	NOUN
cet-1009	49	44	symptoms	symptom	NOUN
cet-1009	49	45	emerge	emerge	VERB
cet-1009	49	46	in	in	ADP
cet-1009	49	47	rats	rat	NOUN
cet-1009	49	48	,	,	PUNCT
cet-1009	49	49	and	and	CCONJ
cet-1009	49	50	after	after	ADP
cet-1009	49	51	the	the	DET
cet-1009	49	52	dosing	dosing	NOUN
cet-1009	49	53	of	of	ADP
cet-1009	49	54	biminkang	biminkang	NOUN
cet-1009	49	55	,	,	PUNCT
cet-1009	49	56	the	the	DET
cet-1009	49	57	experimental	experimental	ADJ
cet-1009	49	58	results	result	NOUN
cet-1009	49	59	show	show	VERB
cet-1009	49	60	that	that	SCONJ
cet-1009	49	61	rhinitis	rhinitis	NOUN
cet-1009	49	62	symptoms	symptom	NOUN
cet-1009	49	63	have	have	AUX
cet-1009	49	64	been	be	AUX
cet-1009	49	65	significantly	significantly	ADV
cet-1009	49	66	improved	improve	VERB
cet-1009	49	67	.	.	PUNCT
cet-1009	50	1	microscopic	microscopic	ADJ
cet-1009	50	2	results	result	NOUN
cet-1009	50	3	of	of	ADP
cet-1009	50	4	the	the	DET
cet-1009	50	5	organization	organization	NOUN
cet-1009	50	6	structure	structure	NOUN
cet-1009	50	7	of	of	ADP
cet-1009	50	8	nasal	nasal	ADJ
cet-1009	50	9	mucosa	mucosa	NOUN
cet-1009	50	10	in	in	ADP
cet-1009	50	11	the	the	DET
cet-1009	50	12	rats	rat	NOUN
cet-1009	50	13	suffering	suffer	VERB
cet-1009	50	14	from	from	ADP
cet-1009	50	15	rhinitis	rhinitis	NOUN
cet-1009	50	16	show	show	NOUN
cet-1009	50	17	that	that	SCONJ
cet-1009	50	18	the	the	DET
cet-1009	50	19	disorder	disorder	NOUN
cet-1009	50	20	,	,	PUNCT
cet-1009	50	21	shedding	shedding	NOUN
cet-1009	50	22	,	,	PUNCT
cet-1009	50	23	edema	edema	NOUN
cet-1009	50	24	and	and	CCONJ
cet-1009	50	25	other	other	ADJ
cet-1009	50	26	symptoms	symptom	NOUN
cet-1009	50	27	emerge	emerge	VERB
cet-1009	50	28	in	in	ADP
cet-1009	50	29	the	the	DET
cet-1009	50	30	mucosal	mucosal	NOUN
cet-1009	50	31	tissue	tissue	NOUN
cet-1009	50	32	.	.	PUNCT
cet-1009	51	1	however	however	ADV
cet-1009	51	2	,	,	PUNCT
cet-1009	51	3	mucosal	mucosal	ADJ
cet-1009	51	4	tissues	tissue	NOUN
cet-1009	51	5	show	show	VERB
cet-1009	51	6	obvious	obvious	ADJ
cet-1009	51	7	improvement	improvement	NOUN
cet-1009	51	8	with	with	ADP
cet-1009	51	9	no	no	DET
cet-1009	51	10	obvious	obvious	ADJ
cet-1009	51	11	structural	structural	ADJ
cet-1009	51	12	damage	damage	NOUN
cet-1009	51	13	and	and	CCONJ
cet-1009	51	14	small	small	ADJ
cet-1009	51	15	amount	amount	NOUN
cet-1009	51	16	of	of	ADP
cet-1009	51	17	infiltration	infiltration	NOUN
cet-1009	51	18	of	of	ADP
cet-1009	51	19	mc	mc	PROPN
cet-1009	51	20	and	and	CCONJ
cet-1009	51	21	eos	eos	PROPN
cet-1009	51	22	after	after	ADP
cet-1009	51	23	the	the	DET
cet-1009	51	24	dosing	dosing	NOUN
cet-1009	51	25	of	of	ADP
cet-1009	51	26	biminkang	biminkang	NOUN
cet-1009	51	27	,	,	PUNCT
cet-1009	51	28	indicating	indicate	VERB
cet-1009	51	29	that	that	SCONJ
cet-1009	51	30	the	the	DET
cet-1009	51	31	biminkang	biminkang	NOUN
cet-1009	51	32	has	have	VERB
cet-1009	51	33	immunopharmacological	immunopharmacological	ADJ
cet-1009	51	34	effect	effect	NOUN
cet-1009	51	35	of	of	ADP
cet-1009	51	36	protecting	protect	VERB
cet-1009	51	37	the	the	DET
cet-1009	51	38	nasal	nasal	ADJ
cet-1009	51	39	mucosa	mucosa	NOUN
cet-1009	51	40	.	.	PUNCT
cet-1009	52	1	in	in	ADP
cet-1009	52	2	normal	normal	ADJ
cet-1009	52	3	organisms	organism	NOUN
cet-1009	52	4	,	,	PUNCT
cet-1009	52	5	the	the	DET
cet-1009	52	6	ige	ige	NOUN
cet-1009	52	7	level	level	NOUN
cet-1009	52	8	is	be	AUX
cet-1009	52	9	low	low	ADJ
cet-1009	52	10	but	but	CCONJ
cet-1009	52	11	it	it	PRON
cet-1009	52	12	will	will	AUX
cet-1009	52	13	increase	increase	VERB
cet-1009	52	14	significantly	significantly	ADV
cet-1009	52	15	when	when	SCONJ
cet-1009	52	16	the	the	DET
cet-1009	52	17	organism	organism	NOUN
cet-1009	52	18	is	be	AUX
cet-1009	52	19	suffering	suffer	VERB
cet-1009	52	20	from	from	ADP
cet-1009	52	21	rhinitis	rhinitis	NOUN
cet-1009	52	22	.	.	PUNCT
cet-1009	53	1	influenced	influence	VERB
cet-1009	53	2	by	by	ADP
cet-1009	53	3	mc	mc	PROPN
cet-1009	53	4	and	and	CCONJ
cet-1009	53	5	eos	eos	PROPN
cet-1009	53	6	,	,	PUNCT
cet-1009	53	7	when	when	SCONJ
cet-1009	53	8	organisms	organism	NOUN
cet-1009	53	9	have	have	AUX
cet-1009	53	10	rhinitis	rhiniti	VERB
cet-1009	53	11	,	,	PUNCT
cet-1009	53	12	the	the	DET
cet-1009	53	13	binding	binding	NOUN
cet-1009	53	14	of	of	ADP
cet-1009	53	15	antigen	antigen	NOUN
cet-1009	53	16	and	and	CCONJ
cet-1009	53	17	ige	ige	PROPN
cet-1009	53	18	cells	cell	NOUN
cet-1009	53	19	release	release	VERB
cet-1009	53	20	pathogenic	pathogenic	ADJ
cet-1009	53	21	medium	medium	NOUN
cet-1009	53	22	like	like	ADP
cet-1009	53	23	histamine	histamine	NOUN
cet-1009	53	24	.	.	PUNCT
cet-1009	54	1	the	the	DET
cet-1009	54	2	results	result	NOUN
cet-1009	54	3	show	show	VERB
cet-1009	54	4	that	that	SCONJ
cet-1009	54	5	the	the	DET
cet-1009	54	6	content	content	NOUN
cet-1009	54	7	of	of	ADP
cet-1009	54	8	ige	ige	PROPN
cet-1009	54	9	in	in	ADP
cet-1009	54	10	rats	rat	NOUN
cet-1009	54	11	is	be	AUX
cet-1009	54	12	significantly	significantly	ADV
cet-1009	54	13	inhibited	inhibit	VERB
cet-1009	54	14	after	after	ADP
cet-1009	54	15	the	the	DET
cet-1009	54	16	dosing	dosing	NOUN
cet-1009	54	17	of	of	ADP
cet-1009	54	18	biminkang	biminkang	NOUN
cet-1009	54	19	,	,	PUNCT
cet-1009	54	20	and	and	CCONJ
cet-1009	54	21	the	the	DET
cet-1009	54	22	treatment	treatment	NOUN
cet-1009	54	23	effect	effect	NOUN
cet-1009	54	24	of	of	ADP
cet-1009	54	25	biminkang	biminkang	NOUN
cet-1009	54	26	is	be	AUX
cet-1009	54	27	better	well	ADJ
cet-1009	54	28	than	than	ADP
cet-1009	54	29	that	that	PRON
cet-1009	54	30	of	of	ADP
cet-1009	54	31	xinqin	xinqin	PROPN
cet-1009	54	32	granules	granule	NOUN
cet-1009	54	33	and	and	CCONJ
cet-1009	54	34	loratadine	loratadine	NOUN
cet-1009	54	35	,	,	PUNCT
cet-1009	54	36	indicating	indicate	VERB
cet-1009	54	37	that	that	SCONJ
cet-1009	54	38	biminkang	biminkang	PROPN
cet-1009	54	39	had	have	VERB
cet-1009	54	40	the	the	DET
cet-1009	54	41	immunopharmacological	immunopharmacological	ADJ
cet-1009	54	42	effect	effect	NOUN
cet-1009	54	43	of	of	ADP
cet-1009	54	44	reducing	reduce	VERB
cet-1009	54	45	the	the	DET
cet-1009	54	46	ige	ige	NOUN
cet-1009	54	47	.	.	PROPN
cet-1009	54	48	4	4	X
cet-1009	54	49	.	.	X
cet-1009	54	50	conclusion	conclusion	NOUN
cet-1009	54	51	based	base	VERB
cet-1009	54	52	on	on	ADP
cet-1009	54	53	the	the	DET
cet-1009	54	54	perspective	perspective	NOUN
cet-1009	54	55	of	of	ADP
cet-1009	54	56	traditional	traditional	ADJ
cet-1009	54	57	chinese	chinese	ADJ
cet-1009	54	58	medicine	medicine	NOUN
cet-1009	54	59	,	,	PUNCT
cet-1009	54	60	this	this	DET
cet-1009	54	61	paper	paper	NOUN
cet-1009	54	62	analyzed	analyze	VERB
cet-1009	54	63	the	the	DET
cet-1009	54	64	pathogenesis	pathogenesis	NOUN
cet-1009	54	65	of	of	ADP
cet-1009	54	66	rhinitis	rhinitis	NOUN
cet-1009	54	67	caused	cause	VERB
cet-1009	54	68	by	by	ADP
cet-1009	54	69	the	the	DET
cet-1009	54	70	deficiency	deficiency	NOUN
cet-1009	54	71	of	of	ADP
cet-1009	54	72	lung	lung	NOUN
cet-1009	54	73	,	,	PUNCT
cet-1009	54	74	spleen	spleen	NOUN
cet-1009	54	75	and	and	CCONJ
cet-1009	54	76	kidney	kidney	NOUN
cet-1009	54	77	,	,	PUNCT
cet-1009	54	78	and	and	CCONJ
cet-1009	54	79	the	the	DET
cet-1009	54	80	invasion	invasion	NOUN
cet-1009	54	81	of	of	ADP
cet-1009	54	82	cold	cold	NOUN
cet-1009	54	83	,	,	PUNCT
cet-1009	54	84	proposed	propose	VERB
cet-1009	54	85	the	the	DET
cet-1009	54	86	combined	combine	VERB
cet-1009	54	87	medicinal	medicinal	ADJ
cet-1009	54	88	components	component	NOUN
cet-1009	54	89	of	of	ADP
cet-1009	54	90	ephedra	ephedra	PROPN
cet-1009	54	91	asarum	asarum	PROPN
cet-1009	54	92	fuzi	fuzi	PROPN
cet-1009	54	93	soup	soup	PROPN
cet-1009	54	94	and	and	CCONJ
cet-1009	54	95	yupingfeng	yupingfeng	PROPN
cet-1009	54	96	san	san	PROPN
cet-1009	54	97	and	and	CCONJ
cet-1009	54	98	conducted	conduct	VERB
cet-1009	54	99	research	research	NOUN
cet-1009	54	100	on	on	ADP
cet-1009	54	101	the	the	DET
cet-1009	54	102	prevention	prevention	NOUN
cet-1009	54	103	and	and	CCONJ
cet-1009	54	104	treatment	treatment	NOUN
cet-1009	54	105	of	of	ADP
cet-1009	54	106	rhinitis	rhinitis	NOUN
cet-1009	54	107	combined	combine	VERB
cet-1009	54	108	with	with	ADP
cet-1009	54	109	the	the	DET
cet-1009	54	110	relevant	relevant	ADJ
cet-1009	54	111	achievements	achievement	NOUN
cet-1009	54	112	in	in	ADP
cet-1009	54	113	immunopharmacology	immunopharmacology	NOUN
cet-1009	54	114	,	,	PUNCT
cet-1009	54	115	providing	provide	VERB
cet-1009	54	116	a	a	DET
cet-1009	54	117	theoretical	theoretical	ADJ
cet-1009	54	118	reference	reference	NOUN
cet-1009	54	119	for	for	ADP
cet-1009	54	120	clinical	clinical	ADJ
cet-1009	54	121	drug	drug	NOUN
cet-1009	54	122	development	development	NOUN
cet-1009	54	123	and	and	CCONJ
cet-1009	54	124	rhinitis	rhinitis	ADJ
cet-1009	54	125	treatment	treatment	NOUN
cet-1009	54	126	.	.	PUNCT
cet-1009	55	1	the	the	DET
cet-1009	55	2	conclusions	conclusion	NOUN
cet-1009	55	3	are	be	AUX
cet-1009	55	4	as	as	ADV
cet-1009	55	5	follow	follow	VERB
cet-1009	55	6	:	:	PUNCT
cet-1009	55	7	(	(	PUNCT
cet-1009	55	8	1	1	X
cet-1009	55	9	)	)	PUNCT
cet-1009	55	10	high	high	ADJ
cet-1009	55	11	dose	dose	PROPN
cet-1009	55	12	of	of	ADP
cet-1009	55	13	binkankang	binkankang	PROPN
cet-1009	55	14	can	can	AUX
cet-1009	55	15	significantly	significantly	ADV
cet-1009	55	16	inhibit	inhibit	VERB
cet-1009	55	17	the	the	DET
cet-1009	55	18	allergic	allergic	ADJ
cet-1009	55	19	contraction	contraction	NOUN
cet-1009	55	20	of	of	ADP
cet-1009	55	21	organisms	organism	NOUN
cet-1009	55	22	and	and	CCONJ
cet-1009	55	23	delay	delay	VERB
cet-1009	55	24	the	the	DET
cet-1009	55	25	hemangiectasis	hemangiectasis	NOUN
cet-1009	55	26	caused	cause	VERB
cet-1009	55	27	by	by	ADP
cet-1009	55	28	histamine	histamine	NOUN
cet-1009	55	29	and	and	CCONJ
cet-1009	55	30	decrease	decrease	VERB
cet-1009	55	31	the	the	DET
cet-1009	55	32	od610	od610	ADJ
cet-1009	55	33	value	value	NOUN
cet-1009	55	34	.	.	PUNCT
cet-1009	56	1	the	the	DET
cet-1009	56	2	medicinal	medicinal	ADJ
cet-1009	56	3	mechanism	mechanism	NOUN
cet-1009	56	4	of	of	ADP
cet-1009	56	5	high	high	ADJ
cet-1009	56	6	dose	dose	PROPN
cet-1009	56	7	of	of	ADP
cet-1009	56	8	binkankang	binkankang	PROPN
cet-1009	56	9	is	be	AUX
cet-1009	56	10	roughly	roughly	ADV
cet-1009	56	11	the	the	DET
cet-1009	56	12	same	same	ADJ
cet-1009	56	13	as	as	ADP
cet-1009	56	14	loratadine	loratadine	NOUN
cet-1009	56	15	.	.	PUNCT
cet-1009	57	1	(	(	PUNCT
cet-1009	57	2	2	2	X
cet-1009	57	3	)	)	PUNCT
cet-1009	57	4	binkankang	binkankang	NOUN
cet-1009	57	5	can	can	AUX
cet-1009	57	6	effectively	effectively	ADV
cet-1009	57	7	protect	protect	VERB
cet-1009	57	8	the	the	DET
cet-1009	57	9	nasal	nasal	PROPN
cet-1009	57	10	mucosa	mucosa	NOUN
cet-1009	57	11	,	,	PUNCT
cet-1009	57	12	reduce	reduce	VERB
cet-1009	57	13	harmful	harmful	ADJ
cet-1009	57	14	nasal	nasal	PROPN
cet-1009	57	15	secreta	secreta	PROPN
cet-1009	57	16	,	,	PUNCT
cet-1009	57	17	and	and	CCONJ
cet-1009	57	18	reduce	reduce	VERB
cet-1009	57	19	the	the	DET
cet-1009	57	20	immunopharmacological	immunopharmacological	ADJ
cet-1009	57	21	effect	effect	NOUN
cet-1009	57	22	of	of	ADP
cet-1009	57	23	mc	mc	PROPN
cet-1009	57	24	number	number	PROPN
cet-1009	57	25	,	,	PUNCT
cet-1009	57	26	eos	eos	PROPN
cet-1009	57	27	,	,	PUNCT
cet-1009	57	28	sp	sp	NOUN
cet-1009	57	29	and	and	CCONJ
cet-1009	57	30	ige	ige	PROPN
cet-1009	57	31	.	.	PUNCT
cet-1009	58	1	the	the	DET
cet-1009	58	2	treatment	treatment	NOUN
cet-1009	58	3	of	of	ADP
cet-1009	58	4	biminkang	biminkang	NOUN
cet-1009	58	5	is	be	AUX
cet-1009	58	6	superior	superior	ADJ
cet-1009	58	7	to	to	ADP
cet-1009	58	8	that	that	PRON
cet-1009	58	9	of	of	ADP
cet-1009	58	10	loratadine	loratadine	NOUN
cet-1009	58	11	,	,	PUNCT
cet-1009	58	12	and	and	CCONJ
cet-1009	58	13	is	be	AUX
cet-1009	58	14	also	also	ADV
cet-1009	58	15	superior	superior	ADJ
cet-1009	58	16	to	to	ADP
cet-1009	58	17	xinqin	xinqin	PROPN
cet-1009	58	18	granule	granule	NOUN
cet-1009	58	19	in	in	ADP
cet-1009	58	20	the	the	DET
cet-1009	58	21	reduction	reduction	NOUN
cet-1009	58	22	of	of	ADP
cet-1009	58	23	eos	eos	PROPN
cet-1009	58	24	and	and	CCONJ
cet-1009	58	25	mc	mc	PROPN
cet-1009	58	26	number	number	NOUN
cet-1009	58	27	.	.	PUNCT
cet-1009	59	1	references	reference	NOUN
cet-1009	59	2	aziza	aziza	PROPN
cet-1009	59	3	a.	a.	PROPN
cet-1009	59	4	,	,	PUNCT
cet-1009	59	5	dermawan	dermawan	PROPN
cet-1009	59	6	a.	a.	PROPN
cet-1009	59	7	,	,	PUNCT
cet-1009	59	8	dewi	dewi	PROPN
cet-1009	59	9	v.	v.	PROPN
cet-1009	59	10	y.	y.	PROPN
cet-1009	59	11	k.	k.	PROPN
cet-1009	59	12	,	,	PUNCT
cet-1009	59	13	2017	2017	NUM
cet-1009	59	14	,	,	PUNCT
cet-1009	59	15	effectiveness	effectiveness	NOUN
cet-1009	59	16	of	of	ADP
cet-1009	59	17	allergic	allergic	ADJ
cet-1009	59	18	rhinitis	rhinitis	NOUN
cet-1009	59	19	management	management	NOUN
cet-1009	59	20	related	relate	VERB
cet-1009	59	21	to	to	ADP
cet-1009	59	22	who	who	PRON
cet-1009	59	23	guideline	guideline	VERB
cet-1009	59	24	on	on	ADP
cet-1009	59	25	allergic	allergic	ADJ
cet-1009	59	26	rhinitis	rhinitis	NOUN
cet-1009	59	27	and	and	CCONJ
cet-1009	59	28	its	its	PRON
cet-1009	59	29	impact	impact	NOUN
cet-1009	59	30	on	on	ADP
cet-1009	59	31	asthma	asthma	NOUN
cet-1009	59	32	(	(	PUNCT
cet-1009	59	33	aria	aria	NOUN
cet-1009	59	34	)	)	PUNCT
cet-1009	59	35	,	,	PUNCT
cet-1009	59	36	3(4	3(4	NUM
cet-1009	59	37	)	)	PUNCT
cet-1009	59	38	,	,	PUNCT
cet-1009	59	39	538	538	NUM
cet-1009	59	40	-	-	SYM
cet-1009	59	41	544	544	NUM
cet-1009	59	42	,	,	PUNCT
cet-1009	59	43	doi	doi	NOUN
cet-1009	59	44	:	:	PUNCT
cet-1009	59	45	10.15850	10.15850	NUM
cet-1009	59	46	/	/	SYM
cet-1009	59	47	amj.v3n4.651	amj.v3n4.651	ADJ
cet-1009	59	48	1265	1265	NUM
cet-1009	59	49	brozmanová	brozmanová	X
cet-1009	59	50	m.	m.	PROPN
cet-1009	59	51	,	,	PUNCT
cet-1009	59	52	calkovský	calkovský	PROPN
cet-1009	59	53	v.	v.	PROPN
cet-1009	59	54	,	,	PUNCT
cet-1009	59	55	plevková	plevková	PROPN
cet-1009	59	56	j.	j.	PROPN
cet-1009	59	57	,	,	PUNCT
cet-1009	59	58	bartos	bartos	PROPN
cet-1009	59	59	v.	v.	PROPN
cet-1009	59	60	,	,	PUNCT
cet-1009	59	61	plank	plank	PROPN
cet-1009	59	62	l.	l.	PROPN
cet-1009	59	63	,	,	PUNCT
cet-1009	59	64	tatár	tatár	NOUN
cet-1009	59	65	m.	m.	NOUN
cet-1009	59	66	,	,	PUNCT
cet-1009	59	67	2006	2006	NUM
cet-1009	59	68	,	,	PUNCT
cet-1009	59	69	early	early	ADJ
cet-1009	59	70	and	and	CCONJ
cet-1009	59	71	late	late	ADJ
cet-1009	59	72	allergic	allergic	ADJ
cet-1009	59	73	phase	phase	NOUN
cet-1009	59	74	related	relate	VERB
cet-1009	59	75	cough	cough	NOUN
cet-1009	59	76	response	response	NOUN
cet-1009	59	77	in	in	ADP
cet-1009	59	78	sensitized	sensitize	VERB
cet-1009	59	79	guinea	guinea	NOUN
cet-1009	59	80	pigs	pig	NOUN
cet-1009	59	81	with	with	ADP
cet-1009	59	82	experimental	experimental	ADJ
cet-1009	59	83	allergic	allergic	ADJ
cet-1009	59	84	rhinitis	rhinitis	NOUN
cet-1009	59	85	,	,	PUNCT
cet-1009	59	86	physiological	physiological	ADJ
cet-1009	59	87	research	research	NOUN
cet-1009	59	88	,	,	PUNCT
cet-1009	59	89	55(5	55(5	NUM
cet-1009	59	90	)	)	PUNCT
cet-1009	59	91	,	,	PUNCT
cet-1009	59	92	577	577	NUM
cet-1009	59	93	.	.	PUNCT
cet-1009	60	1	canonica	canonica	PROPN
cet-1009	60	2	g.	g.	PROPN
cet-1009	60	3	,	,	PUNCT
cet-1009	60	4	baiardini	baiardini	PROPN
cet-1009	60	5	i.	i.	PROPN
cet-1009	60	6	,	,	PUNCT
cet-1009	60	7	canonica	canonica	PROPN
cet-1009	60	8	g.	g.	PROPN
cet-1009	60	9	,	,	PUNCT
cet-1009	60	10	2010	2010	NUM
cet-1009	60	11	,	,	PUNCT
cet-1009	60	12	early	early	ADJ
cet-1009	60	13	phase	phase	NOUN
cet-1009	60	14	resolution	resolution	NOUN
cet-1009	60	15	of	of	ADP
cet-1009	60	16	mucosal	mucosal	ADJ
cet-1009	60	17	eosinophilic	eosinophilic	ADJ
cet-1009	60	18	inflammation	inflammation	NOUN
cet-1009	60	19	in	in	ADP
cet-1009	60	20	allergic	allergic	ADJ
cet-1009	60	21	rhinitis	rhinitis	NOUN
cet-1009	60	22	,	,	PUNCT
cet-1009	60	23	respiratory	respiratory	ADJ
cet-1009	60	24	research	research	NOUN
cet-1009	60	25	,	,	PUNCT
cet-1009	60	26	11(1	11(1	NUM
cet-1009	60	27	)	)	PUNCT
cet-1009	60	28	,	,	PUNCT
cet-1009	60	29	54	54	NUM
cet-1009	60	30	,	,	PUNCT
cet-1009	60	31	doi	doi	NOUN
cet-1009	60	32	:	:	PUNCT
cet-1009	60	33	10.1186/1465	10.1186/1465	NUM
cet-1009	60	34	-	-	PUNCT
cet-1009	60	35	9921	9921	NUM
cet-1009	60	36	-	-	SYM
cet-1009	60	37	11	11	NUM
cet-1009	60	38	-	-	SYM
cet-1009	60	39	54	54	NUM
cet-1009	60	40	ciprandi	ciprandi	NOUN
cet-1009	60	41	g.	g.	PROPN
cet-1009	60	42	,	,	PUNCT
cet-1009	60	43	2008	2008	NUM
cet-1009	60	44	,	,	PUNCT
cet-1009	60	45	allergic	allergic	ADJ
cet-1009	60	46	rhinitis	rhinitis	NOUN
cet-1009	60	47	and	and	CCONJ
cet-1009	60	48	its	its	PRON
cet-1009	60	49	impact	impact	NOUN
cet-1009	60	50	on	on	ADP
cet-1009	60	51	asthma	asthma	NOUN
cet-1009	60	52	,	,	PUNCT
cet-1009	60	53	italian	italian	ADJ
cet-1009	60	54	journal	journal	NOUN
cet-1009	60	55	of	of	ADP
cet-1009	60	56	allergy	allergy	PROPN
cet-1009	60	57	&	&	CCONJ
cet-1009	60	58	clinical	clinical	ADJ
cet-1009	60	59	immunology	immunology	NOUN
cet-1009	60	60	,	,	PUNCT
cet-1009	60	61	18(1	18(1	NUM
cet-1009	60	62	)	)	PUNCT
cet-1009	60	63	,	,	PUNCT
cet-1009	60	64	1	1	NUM
cet-1009	60	65	-	-	SYM
cet-1009	60	66	8	8	NUM
cet-1009	60	67	,	,	PUNCT
cet-1009	60	68	doi	doi	NOUN
cet-1009	60	69	:	:	PUNCT
cet-1009	60	70	10.1201	10.1201	NUM
cet-1009	60	71	/	/	SYM
cet-1009	60	72	b14160	b14160	PROPN
cet-1009	60	73	-	-	PUNCT
cet-1009	60	74	27	27	NUM
cet-1009	60	75	gelfand	gelfand	PROPN
cet-1009	60	76	e.	e.	PROPN
cet-1009	60	77	w.	w.	PROPN
cet-1009	60	78	,	,	PUNCT
cet-1009	60	79	2004	2004	NUM
cet-1009	60	80	,	,	PUNCT
cet-1009	60	81	inflammatory	inflammatory	ADJ
cet-1009	60	82	mediators	mediator	NOUN
cet-1009	60	83	in	in	ADP
cet-1009	60	84	allergic	allergic	ADJ
cet-1009	60	85	rhinitis	rhinitis	NOUN
cet-1009	60	86	,	,	PUNCT
cet-1009	60	87	journal	journal	NOUN
cet-1009	60	88	of	of	ADP
cet-1009	60	89	allergy	allergy	PROPN
cet-1009	60	90	&	&	CCONJ
cet-1009	60	91	clinical	clinical	ADJ
cet-1009	60	92	immunology	immunology	NOUN
cet-1009	60	93	,	,	PUNCT
cet-1009	60	94	114(5	114(5	NUM
cet-1009	60	95	)	)	PUNCT
cet-1009	60	96	,	,	PUNCT
cet-1009	60	97	s135	s135	PROPN
cet-1009	60	98	,	,	PUNCT
cet-1009	60	99	doi	doi	NOUN
cet-1009	60	100	:	:	PUNCT
cet-1009	60	101	10.1016	10.1016	NUM
cet-1009	60	102	/	/	SYM
cet-1009	60	103	j.jaci.2004.08.043	j.jaci.2004.08.043	PROPN
cet-1009	60	104	hansen	hansen	PROPN
cet-1009	60	105	i.	i.	PROPN
cet-1009	60	106	,	,	PUNCT
cet-1009	60	107	klimek	klimek	PROPN
cet-1009	60	108	l.	l.	PROPN
cet-1009	60	109	,	,	PUNCT
cet-1009	60	110	mösges	mösges	PROPN
cet-1009	60	111	r.	r.	PROPN
cet-1009	60	112	,	,	PUNCT
cet-1009	60	113	hörmann	hörmann	PROPN
cet-1009	60	114	k.	k.	PROPN
cet-1009	60	115	,	,	PUNCT
cet-1009	60	116	2004	2004	NUM
cet-1009	60	117	,	,	PUNCT
cet-1009	60	118	mediators	mediator	NOUN
cet-1009	60	119	of	of	ADP
cet-1009	60	120	inflammation	inflammation	NOUN
cet-1009	60	121	in	in	ADP
cet-1009	60	122	the	the	DET
cet-1009	60	123	early	early	ADJ
cet-1009	60	124	and	and	CCONJ
cet-1009	60	125	the	the	DET
cet-1009	60	126	late	late	ADJ
cet-1009	60	127	phase	phase	NOUN
cet-1009	60	128	of	of	ADP
cet-1009	60	129	allergic	allergic	ADJ
cet-1009	60	130	rhinitis	rhinitis	NOUN
cet-1009	60	131	,	,	PUNCT
cet-1009	60	132	current	current	ADJ
cet-1009	60	133	opinion	opinion	NOUN
cet-1009	60	134	in	in	ADP
cet-1009	60	135	allergy	allergy	PROPN
cet-1009	60	136	&	&	CCONJ
cet-1009	60	137	clinical	clinical	ADJ
cet-1009	60	138	immunology	immunology	NOUN
cet-1009	60	139	,	,	PUNCT
cet-1009	60	140	4(3	4(3	NUM
cet-1009	60	141	)	)	PUNCT
cet-1009	60	142	,	,	PUNCT
cet-1009	60	143	159	159	NUM
cet-1009	60	144	,	,	PUNCT
cet-1009	60	145	doi	doi	NOUN
cet-1009	60	146	:	:	PUNCT
cet-1009	60	147	10.1097/00130832200406000	10.1097/00130832200406000	NUM
cet-1009	60	148	-	-	SYM
cet-1009	60	149	00004	00004	NUM
cet-1009	60	150	liu	liu	PROPN
cet-1009	60	151	w.	w.	PROPN
cet-1009	60	152	,	,	PUNCT
cet-1009	60	153	li	li	PROPN
cet-1009	60	154	d.	d.	PROPN
cet-1009	60	155	,	,	PUNCT
cet-1009	60	156	chen	chen	PROPN
cet-1009	60	157	y.	y.	PROPN
cet-1009	60	158	,	,	PUNCT
cet-1009	60	159	sun	sun	PROPN
cet-1009	60	160	c.	c.	PROPN
cet-1009	60	161	,	,	PUNCT
cet-1009	60	162	wang	wang	PROPN
cet-1009	60	163	j.	j.	PROPN
cet-1009	60	164	,	,	PUNCT
cet-1009	60	165	zhou	zhou	PROPN
cet-1009	60	166	l.	l.	PROPN
cet-1009	60	167	,	,	PUNCT
cet-1009	60	168	2014	2014	NUM
cet-1009	60	169	,	,	PUNCT
cet-1009	60	170	anti	anti	ADJ
cet-1009	60	171	-	-	ADJ
cet-1009	60	172	inflammatory	inflammatory	ADJ
cet-1009	60	173	effect	effect	NOUN
cet-1009	60	174	of	of	ADP
cet-1009	60	175	il-37b	il-37b	ADJ
cet-1009	60	176	in	in	ADP
cet-1009	60	177	children	child	NOUN
cet-1009	60	178	with	with	ADP
cet-1009	60	179	allergic	allergic	ADJ
cet-1009	60	180	rhinitis	rhinitis	NOUN
cet-1009	60	181	,	,	PUNCT
cet-1009	60	182	mediators	mediator	NOUN
cet-1009	60	183	of	of	ADP
cet-1009	60	184	inflammation	inflammation	NOUN
cet-1009	60	185	,	,	PUNCT
cet-1009	60	186	2014(7	2014(7	NUM
cet-1009	60	187	)	)	PUNCT
cet-1009	60	188	,	,	PUNCT
cet-1009	60	189	746846	746846	NUM
cet-1009	60	190	,	,	PUNCT
cet-1009	60	191	doi	doi	NOUN
cet-1009	60	192	:	:	PUNCT
cet-1009	60	193	10.1155/2014/746846	10.1155/2014/746846	NUM
cet-1009	60	194	mandhane	mandhane	PROPN
cet-1009	60	195	s.	s.	PROPN
cet-1009	60	196	n.	n.	PROPN
cet-1009	60	197	,	,	PUNCT
cet-1009	60	198	shah	shah	PROPN
cet-1009	60	199	j.	j.	PROPN
cet-1009	60	200	h.	h.	PROPN
cet-1009	60	201	,	,	PUNCT
cet-1009	60	202	thennati	thennati	PROPN
cet-1009	60	203	r.	r.	PROPN
cet-1009	60	204	,	,	PUNCT
cet-1009	60	205	2011	2011	NUM
cet-1009	60	206	,	,	PUNCT
cet-1009	60	207	allergic	allergic	ADJ
cet-1009	60	208	rhinitis	rhinitis	NOUN
cet-1009	60	209	:	:	PUNCT
cet-1009	60	210	an	an	DET
cet-1009	60	211	update	update	NOUN
cet-1009	60	212	on	on	ADP
cet-1009	60	213	disease	disease	NOUN
cet-1009	60	214	,	,	PUNCT
cet-1009	60	215	present	present	ADJ
cet-1009	60	216	treatments	treatment	NOUN
cet-1009	60	217	and	and	CCONJ
cet-1009	60	218	future	future	ADJ
cet-1009	60	219	prospects	prospect	NOUN
cet-1009	60	220	,	,	PUNCT
cet-1009	60	221	international	international	ADJ
cet-1009	60	222	immunopharmacology	immunopharmacology	NOUN
cet-1009	60	223	,	,	PUNCT
cet-1009	60	224	11(11	11(11	NUM
cet-1009	60	225	)	)	PUNCT
cet-1009	60	226	,	,	PUNCT
cet-1009	60	227	1646	1646	NUM
cet-1009	60	228	-	-	SYM
cet-1009	60	229	1662	1662	NUM
cet-1009	60	230	,	,	PUNCT
cet-1009	60	231	doi	doi	NOUN
cet-1009	60	232	:	:	PUNCT
cet-1009	60	233	10.1016	10.1016	NUM
cet-1009	60	234	/	/	SYM
cet-1009	60	235	j.intimp.2011.07.005	j.intimp.2011.07.005	PROPN
cet-1009	60	236	marple	marple	PROPN
cet-1009	60	237	b.	b.	PROPN
cet-1009	60	238	f.	f.	PROPN
cet-1009	60	239	,	,	PUNCT
cet-1009	60	240	2008	2008	NUM
cet-1009	60	241	,	,	PUNCT
cet-1009	60	242	targeting	target	VERB
cet-1009	60	243	congestion	congestion	NOUN
cet-1009	60	244	in	in	ADP
cet-1009	60	245	allergic	allergic	ADJ
cet-1009	60	246	rhinitis	rhinitis	NOUN
cet-1009	60	247	:	:	PUNCT
cet-1009	60	248	the	the	DET
cet-1009	60	249	importance	importance	NOUN
cet-1009	60	250	of	of	ADP
cet-1009	60	251	intranasal	intranasal	ADJ
cet-1009	60	252	corticosteroids	corticosteroid	NOUN
cet-1009	60	253	,	,	PUNCT
cet-1009	60	254	allergy	allergy	NOUN
cet-1009	60	255	&	&	CCONJ
cet-1009	60	256	asthma	asthma	PROPN
cet-1009	60	257	proceedings	proceeding	NOUN
cet-1009	60	258	,	,	PUNCT
cet-1009	60	259	29(3	29(3	NUM
cet-1009	60	260	)	)	PUNCT
cet-1009	60	261	,	,	PUNCT
cet-1009	60	262	232	232	NUM
cet-1009	60	263	,	,	PUNCT
cet-1009	60	264	doi	doi	NOUN
cet-1009	60	265	:	:	PUNCT
cet-1009	60	266	10.2500	10.2500	NUM
cet-1009	60	267	/	/	SYM
cet-1009	60	268	aap.2008.29.3110	aap.2008.29.3110	ADP
cet-1009	60	269	miyahara	miyahara	PROPN
cet-1009	60	270	s.	s.	PROPN
cet-1009	60	271	,	,	PUNCT
cet-1009	60	272	miyahara	miyahara	PROPN
cet-1009	60	273	n.	n.	NOUN
cet-1009	60	274	,	,	PUNCT
cet-1009	60	275	matsubara	matsubara	PROPN
cet-1009	60	276	s.	s.	PROPN
cet-1009	60	277	,	,	PUNCT
cet-1009	60	278	takeda	takeda	PROPN
cet-1009	60	279	k.	k.	PROPN
cet-1009	60	280	,	,	PUNCT
cet-1009	60	281	koya	koya	PROPN
cet-1009	60	282	t.	t.	PROPN
cet-1009	60	283	,	,	PUNCT
cet-1009	60	284	gelfand	gelfand	PROPN
cet-1009	60	285	e.	e.	PROPN
cet-1009	60	286	w.	w.	PROPN
cet-1009	60	287	,	,	PUNCT
cet-1009	60	288	2006	2006	NUM
cet-1009	60	289	,	,	PUNCT
cet-1009	60	290	il-13	il-13	PUNCT
cet-1009	60	291	is	be	AUX
cet-1009	60	292	essential	essential	ADJ
cet-1009	60	293	to	to	ADP
cet-1009	60	294	the	the	DET
cet-1009	60	295	late	late	ADJ
cet-1009	60	296	-	-	PUNCT
cet-1009	60	297	phase	phase	NOUN
cet-1009	60	298	response	response	NOUN
cet-1009	60	299	in	in	ADP
cet-1009	60	300	allergic	allergic	ADJ
cet-1009	60	301	rhinitis	rhinitis	NOUN
cet-1009	60	302	,	,	PUNCT
cet-1009	60	303	journal	journal	NOUN
cet-1009	60	304	of	of	ADP
cet-1009	60	305	allergy	allergy	PROPN
cet-1009	60	306	&	&	CCONJ
cet-1009	60	307	clinical	clinical	ADJ
cet-1009	60	308	immunology	immunology	NOUN
cet-1009	60	309	,	,	PUNCT
cet-1009	60	310	118(5	118(5	NUM
cet-1009	60	311	)	)	PUNCT
cet-1009	60	312	,	,	PUNCT
cet-1009	60	313	1110	1110	NUM
cet-1009	60	314	-	-	SYM
cet-1009	60	315	1116	1116	NUM
cet-1009	60	316	,	,	PUNCT
cet-1009	60	317	doi	doi	NOUN
cet-1009	60	318	:	:	PUNCT
cet-1009	60	319	10.1016	10.1016	NUM
cet-1009	60	320	/	/	SYM
cet-1009	60	321	j.jaci.2006.06.014	j.jaci.2006.06.014	PROPN
cet-1009	60	322	nabe	nabe	PROPN
cet-1009	60	323	t.	t.	PROPN
cet-1009	60	324	,	,	PUNCT
cet-1009	60	325	mizutani	mizutani	PROPN
cet-1009	60	326	n.	n.	PROPN
cet-1009	60	327	,	,	PUNCT
cet-1009	60	328	shimizu	shimizu	PROPN
cet-1009	60	329	k.	k.	PROPN
cet-1009	60	330	,	,	PUNCT
cet-1009	60	331	takenaka	takenaka	PROPN
cet-1009	60	332	h.	h.	PROPN
cet-1009	60	333	,	,	PUNCT
cet-1009	60	334	kohno	kohno	PROPN
cet-1009	60	335	s.	s.	PROPN
cet-1009	60	336	,	,	PUNCT
cet-1009	60	337	2014	2014	NUM
cet-1009	60	338	,	,	PUNCT
cet-1009	60	339	development	development	NOUN
cet-1009	60	340	of	of	ADP
cet-1009	60	341	pollen	pollen	NOUN
cet-1009	60	342	-	-	PUNCT
cet-1009	60	343	induced	induce	VERB
cet-1009	60	344	allergic	allergic	ADJ
cet-1009	60	345	rhinitis	rhinitis	NOUN
cet-1009	60	346	with	with	ADP
cet-1009	60	347	early	early	ADJ
cet-1009	60	348	and	and	CCONJ
cet-1009	60	349	late	late	ADJ
cet-1009	60	350	phase	phase	NOUN
cet-1009	60	351	nasal	nasal	NOUN
cet-1009	60	352	blockage	blockage	NOUN
cet-1009	60	353	in	in	ADP
cet-1009	60	354	guinea	guinea	NOUN
cet-1009	60	355	pigs	pig	NOUN
cet-1009	60	356	,	,	PUNCT
cet-1009	60	357	inflammation	inflammation	NOUN
cet-1009	60	358	research	research	NOUN
cet-1009	60	359	,	,	PUNCT
cet-1009	60	360	47(9	47(9	NOUN
cet-1009	60	361	)	)	PUNCT
cet-1009	60	362	,	,	PUNCT
cet-1009	60	363	369	369	NUM
cet-1009	60	364	-	-	SYM
cet-1009	60	365	374	374	NUM
cet-1009	60	366	,	,	PUNCT
cet-1009	60	367	doi	doi	NOUN
cet-1009	60	368	:	:	PUNCT
cet-1009	60	369	10.1007	10.1007	NUM
cet-1009	60	370	/	/	SYM
cet-1009	60	371	s000110050346	s000110050346	ADJ
cet-1009	60	372	naclerio	naclerio	NOUN
cet-1009	60	373	r.	r.	PROPN
cet-1009	60	374	m.	m.	PROPN
cet-1009	60	375	,	,	PUNCT
cet-1009	60	376	2010	2010	NUM
cet-1009	60	377	,	,	PUNCT
cet-1009	60	378	pathophysiology	pathophysiology	NOUN
cet-1009	60	379	of	of	ADP
cet-1009	60	380	perennial	perennial	ADJ
cet-1009	60	381	allergic	allergic	ADJ
cet-1009	60	382	rhinitis	rhinitis	NOUN
cet-1009	60	383	,	,	PUNCT
cet-1009	60	384	allergy	allergy	NOUN
cet-1009	60	385	,	,	PUNCT
cet-1009	60	386	52(s36	52(s36	NUM
cet-1009	60	387	)	)	PUNCT
cet-1009	60	388	,	,	PUNCT
cet-1009	60	389	7	7	NUM
cet-1009	60	390	-	-	SYM
cet-1009	60	391	13	13	NUM
cet-1009	60	392	,	,	PUNCT
cet-1009	60	393	doi	doi	NOUN
cet-1009	60	394	:	:	PUNCT
cet-1009	60	395	10.1111	10.1111	NUM
cet-1009	60	396	/	/	SYM
cet-1009	60	397	j.1398	j.1398	ADP
cet-1009	60	398	-	-	PUNCT
cet-1009	60	399	9995.1997.tb04816.x	9995.1997.tb04816.x	NUM
cet-1009	60	400	ofworkshops	ofworkshop	NOUN
cet-1009	60	401	m.	m.	NOUN
cet-1009	60	402	,	,	PUNCT
cet-1009	60	403	2004	2004	NUM
cet-1009	60	404	,	,	PUNCT
cet-1009	60	405	aria	aria	NOUN
cet-1009	60	406	in	in	ADP
cet-1009	60	407	the	the	DET
cet-1009	60	408	pharmacy	pharmacy	NOUN
cet-1009	60	409	:	:	PUNCT
cet-1009	60	410	management	management	NOUN
cet-1009	60	411	of	of	ADP
cet-1009	60	412	allergic	allergic	ADJ
cet-1009	60	413	rhinitis	rhinitis	NOUN
cet-1009	60	414	symptoms	symptom	NOUN
cet-1009	60	415	in	in	ADP
cet-1009	60	416	the	the	DET
cet-1009	60	417	pharmacy	pharmacy	NOUN
cet-1009	60	418	,	,	PUNCT
cet-1009	60	419	allergic	allergic	ADJ
cet-1009	60	420	rhinitis	rhinitis	NOUN
cet-1009	60	421	and	and	CCONJ
cet-1009	60	422	its	its	PRON
cet-1009	60	423	impact	impact	NOUN
cet-1009	60	424	on	on	ADP
cet-1009	60	425	asthma	asthma	NOUN
cet-1009	60	426	,	,	PUNCT
cet-1009	60	427	allergy	allergy	NOUN
cet-1009	60	428	,	,	PUNCT
cet-1009	60	429	59(4	59(4	NUM
cet-1009	60	430	)	)	PUNCT
cet-1009	60	431	,	,	PUNCT
cet-1009	61	1	373	373	NUM
cet-1009	61	2	.	.	PUNCT
cet-1009	61	3	doi	doi	NOUN
cet-1009	61	4	:	:	PUNCT
cet-1009	61	5	10.1111	10.1111	NUM
cet-1009	61	6	/	/	SYM
cet-1009	61	7	j.1398	j.1398	PROPN
cet-1009	61	8	-	-	PUNCT
cet-1009	61	9	9995.2003.00468.x	9995.2003.00468.x	NUM
cet-1009	61	10	passalacqua	passalacqua	NOUN
cet-1009	61	11	g.	g.	PROPN
cet-1009	61	12	,	,	PUNCT
cet-1009	61	13	durham	durham	PROPN
cet-1009	61	14	s.r	s.r	PROPN
cet-1009	61	15	.	.	PROPN
cet-1009	61	16	,	,	PUNCT
cet-1009	61	17	2007	2007	NUM
cet-1009	61	18	,	,	PUNCT
cet-1009	61	19	allergic	allergic	ADJ
cet-1009	61	20	rhinitis	rhinitis	NOUN
cet-1009	61	21	and	and	CCONJ
cet-1009	61	22	its	its	PRON
cet-1009	61	23	impact	impact	NOUN
cet-1009	61	24	on	on	ADP
cet-1009	61	25	asthma	asthma	NOUN
cet-1009	61	26	update	update	NOUN
cet-1009	61	27	:	:	PUNCT
cet-1009	61	28	allergen	allergen	NOUN
cet-1009	61	29	immunotherapy	immunotherapy	NOUN
cet-1009	61	30	,	,	PUNCT
cet-1009	61	31	j	j	PROPN
cet-1009	61	32	allergy	allergy	PROPN
cet-1009	61	33	clin	clin	PROPN
cet-1009	61	34	immunol	immunol	PROPN
cet-1009	61	35	,	,	PUNCT
cet-1009	61	36	119(4	119(4	NUM
cet-1009	61	37	)	)	PUNCT
cet-1009	61	38	,	,	PUNCT
cet-1009	61	39	881	881	NUM
cet-1009	61	40	-	-	SYM
cet-1009	61	41	891	891	NUM
cet-1009	61	42	,	,	PUNCT
cet-1009	61	43	doi	doi	NOUN
cet-1009	61	44	:	:	PUNCT
cet-1009	61	45	10.1016	10.1016	NUM
cet-1009	61	46	/	/	SYM
cet-1009	61	47	j.jaci.2007.01.045	j.jaci.2007.01.045	ADV
cet-1009	61	48	scadding	scadde	VERB
cet-1009	61	49	g.k	g.k	PROPN
cet-1009	61	50	.	.	PROPN
cet-1009	61	51	,	,	PUNCT
cet-1009	61	52	2008	2008	NUM
cet-1009	61	53	,	,	PUNCT
cet-1009	61	54	allergic	allergic	ADJ
cet-1009	61	55	rhinitis	rhinitis	NOUN
cet-1009	61	56	in	in	ADP
cet-1009	61	57	children	child	NOUN
cet-1009	61	58	.	.	PUNCT
cet-1009	62	1	paediatrics	paediatric	NOUN
cet-1009	62	2	&	&	CCONJ
cet-1009	62	3	child	child	PROPN
cet-1009	62	4	health	health	PROPN
cet-1009	62	5	,	,	PUNCT
cet-1009	62	6	18(7	18(7	NUM
cet-1009	62	7	)	)	PUNCT
cet-1009	62	8	,	,	PUNCT
cet-1009	62	9	323	323	NUM
cet-1009	62	10	-	-	SYM
cet-1009	62	11	328	328	NUM
cet-1009	62	12	,	,	PUNCT
cet-1009	62	13	doi	doi	NOUN
cet-1009	62	14	:	:	PUNCT
cet-1009	62	15	10.1111	10.1111	NUM
cet-1009	62	16	/	/	SYM
cet-1009	62	17	j.1440	j.1440	PROPN
cet-1009	62	18	-	-	PUNCT
cet-1009	62	19	1754.2010.01779.x	1754.2010.01779.x	NUM
cet-1009	62	20	spector	spector	PROPN
cet-1009	62	21	s.	s.	PROPN
cet-1009	62	22	,	,	PUNCT
cet-1009	62	23	wallace	wallace	PROPN
cet-1009	62	24	d.	d.	PROPN
cet-1009	62	25	,	,	PUNCT
cet-1009	62	26	nicklas	nicklas	PROPN
cet-1009	62	27	r.	r.	PROPN
cet-1009	62	28	,	,	PUNCT
cet-1009	62	29	portnoy	portnoy	PROPN
cet-1009	62	30	j.	j.	PROPN
cet-1009	62	31	,	,	PUNCT
cet-1009	62	32	blessingmoore	blessingmoore	ADP
cet-1009	62	33	j.	j.	PROPN
cet-1009	62	34	,	,	PUNCT
cet-1009	62	35	bernstein	bernstein	PROPN
cet-1009	62	36	d.	d.	PROPN
cet-1009	62	37	,	,	PUNCT
cet-1009	62	38	2011	2011	NUM
cet-1009	62	39	,	,	PUNCT
cet-1009	62	40	comments	comment	NOUN
cet-1009	62	41	on	on	ADP
cet-1009	62	42	allergic	allergic	ADJ
cet-1009	62	43	rhinitis	rhinitis	NOUN
cet-1009	62	44	and	and	CCONJ
cet-1009	62	45	its	its	PRON
cet-1009	62	46	impact	impact	NOUN
cet-1009	62	47	on	on	ADP
cet-1009	62	48	asthma	asthma	NOUN
cet-1009	62	49	(	(	PUNCT
cet-1009	62	50	aria	aria	NOUN
cet-1009	62	51	)	)	PUNCT
cet-1009	62	52	guidelines	guideline	NOUN
cet-1009	62	53	,	,	PUNCT
cet-1009	62	54	journal	journal	NOUN
cet-1009	62	55	of	of	ADP
cet-1009	62	56	allergy	allergy	PROPN
cet-1009	62	57	&	&	CCONJ
cet-1009	62	58	clinical	clinical	ADJ
cet-1009	62	59	immunology	immunology	NOUN
cet-1009	62	60	,	,	PUNCT
cet-1009	62	61	127(6	127(6	NUM
cet-1009	62	62	)	)	PUNCT
cet-1009	62	63	,	,	PUNCT
cet-1009	62	64	1641	1641	NUM
cet-1009	62	65	,	,	PUNCT
cet-1009	62	66	doi	doi	NOUN
cet-1009	62	67	:	:	PUNCT
cet-1009	62	68	10.1016	10.1016	NUM
cet-1009	62	69	/	/	SYM
cet-1009	62	70	j.jaci.2011.01.071	j.jaci.2011.01.071	PROPN
cet-1009	62	71	1266	1266	NUM